<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81208</article-id><article-id pub-id-type="doi">10.7554/eLife.81208</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>CCR1 mediates Müller cell activation and photoreceptor cell death in macular and retinal degeneration</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-285807"><name><surname>Elbaz-Hayoun</surname><given-names>Sarah</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0006-8605-5775</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285808"><name><surname>Rinsky</surname><given-names>Batya</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285809"><name><surname>Hagbi-Levi</surname><given-names>Shira</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2891-0079</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285810"><name><surname>Grunin</surname><given-names>Michelle</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3155-2858</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-63570"><name><surname>Chowers</surname><given-names>Itay</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1897-4973</contrib-id><email>chowerslab@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cqmqj90</institution-id><institution>Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem</institution></institution-wrap><addr-line><named-content content-type="city">Jerusalem</named-content></addr-line><country>Israel</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Bernstein</surname><given-names>Audrey M</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040kfrw16</institution-id><institution>State University of New York Upstate Medical University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>30</day><month>10</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e81208</elocation-id><history><date date-type="received" iso-8601-date="2022-06-19"><day>19</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-10-04"><day>04</day><month>10</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2023-01-03"><day>03</day><month>01</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.01.03.522541"/></event></pub-history><permissions><copyright-statement>© 2023, Elbaz-Hayoun et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Elbaz-Hayoun et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81208-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-81208-figures-v1.pdf"/><abstract><p>Mononuclear cells are involved in the pathogenesis of retinal diseases, including age-related macular degeneration (AMD). Here, we examined the mechanisms that underlie macrophage-driven retinal cell death. Monocytes were extracted from patients with AMD and differentiated into macrophages (hMdɸs), which were characterized based on proteomics, gene expression, and ex vivo and in vivo properties. Using bioinformatics, we identified the signaling pathway involved in macrophage-driven retinal cell death, and we assessed the therapeutic potential of targeting this pathway. We found that M2a hMdɸs were associated with retinal cell death in retinal explants and following adoptive transfer in a photic injury model. Moreover, M2a hMdɸs express several CCRI (C-C chemokine receptor type 1) ligands. Importantly, CCR1 was upregulated in Müller cells in models of retinal injury and aging, and CCR1 expression was correlated with retinal damage. Lastly, inhibiting CCR1 reduced photic-induced retinal damage, photoreceptor cell apoptosis, and retinal inflammation. These data suggest that hMdɸs, CCR1, and Müller cells work together to drive retinal and macular degeneration, suggesting that CCR1 may serve as a target for treating these sight-threatening conditions.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>CCR1</kwd><kwd>macrophage</kwd><kwd>Müller cell</kwd><kwd>atrophic AMD</kwd><kwd>retina</kwd><kwd>gliosis</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003977</institution-id><institution>Israel Science Foundation</institution></institution-wrap></funding-source><award-id>1006/13</award-id><principal-award-recipient><name><surname>Elbaz-Hayoun</surname><given-names>Sarah</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003977</institution-id><institution>Israel Science Foundation</institution></institution-wrap></funding-source><award-id>3485/19</award-id><principal-award-recipient><name><surname>Elbaz-Hayoun</surname><given-names>Sarah</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006544</institution-id><institution>Israeli Ministry of Health</institution></institution-wrap></funding-source><award-id>9184</award-id><principal-award-recipient><name><surname>Elbaz-Hayoun</surname><given-names>Sarah</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A novel therapy for a common blinding retinal disease uses an innovative CCR1 blocking-based strategy.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Age-related macular degeneration (AMD) is the leading cause of irreversible blindness among the elderly in the Western world (<xref ref-type="bibr" rid="bib29">Friedman et al., 2004</xref>; <xref ref-type="bibr" rid="bib83">Resnikoff et al., 2004</xref>; <xref ref-type="bibr" rid="bib99">Singer et al., 2012</xref>). Atrophic AMD (aAMD, also known as ‘dry’ AMD) is characterized by the progressive loss of retinal pigment epithelial (RPE) cells and photoreceptor cells, which can coalesce and cause geographic atrophy in the macular region. In contrast, neovascular AMD (nvAMD, also known as ‘wet’ AMD) is characterized by choroidal neovascularization (CNV) (<xref ref-type="bibr" rid="bib49">Leeuwen et al., 2003</xref>; <xref ref-type="bibr" rid="bib43">Joachim et al., 2015</xref>). Although anti-VEGF (vascular endothelial growth factor) compounds are used to treat nvAMD by reducing leakage and the progression of CNV (<xref ref-type="bibr" rid="bib84">Rosenfeld et al., 2006</xref>), treatments that slow the progression of atrophy and vision loss in aAMD are lacking and therefore urgently needed.</p><p>AMD is caused by multiple factors, including senescence, genetic factors, environmental factors, and impaired immune system function (<xref ref-type="bibr" rid="bib10">Bowes Rickman et al., 2013</xref>). Moreover, inflammation is a major factor involved in the pathogenesis of AMD (<xref ref-type="bibr" rid="bib6">Augustin and Kirchhof, 2009</xref>). Polymorphisms in several genes encoding complement factor proteins such as complement factor H (<xref ref-type="bibr" rid="bib100">Smailhodzic et al., 2012</xref>), C3 (<xref ref-type="bibr" rid="bib118">Yates et al., 2007</xref>), and C5 <xref ref-type="bibr" rid="bib7">Baas et al., 2010</xref> have been associated with both forms of AMD, suggesting an underlying dysregulation of the complement cascade. Increased levels of C-reactive protein and complement activation have also been measured in the plasma of patients with AMD (<xref ref-type="bibr" rid="bib90">Seddon et al., 2004</xref>), and histological analyses of AMD eyes revealed the presence of macrophages in the vicinity of the atrophic lesion (<xref ref-type="bibr" rid="bib15">Cao et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Lad et al., 2015</xref>; <xref ref-type="bibr" rid="bib14">Buschini et al., 2011</xref>), as well as in drusen (<xref ref-type="bibr" rid="bib77">Penfold et al., 2001</xref>) and the subretinal space (<xref ref-type="bibr" rid="bib93">Sennlaub et al., 2013</xref>). Moreover, a non-resolving immune response involving the sustained recruitment of immune cells has been shown to contribute to the development of various neurodegenerative diseases, including AMD (<xref ref-type="bibr" rid="bib72">Nathan and Ding, 2010</xref>; <xref ref-type="bibr" rid="bib5">Apte et al., 2006</xref>). Thus, determining the precise role that immune cells play in the onset and progression of AMD is a necessary step toward developing new therapeutic approaches.</p><p>We previously showed that peripheral blood mononuclear cells (PBMCs) obtained from patients with AMD have a pro-inflammatory gene expression profile (<xref ref-type="bibr" rid="bib48">Lederman et al., 2010</xref>). In addition, other groups have shown that blocking monocyte recruitment reduces the degree of retinal injury in various animal models (<xref ref-type="bibr" rid="bib93">Sennlaub et al., 2013</xref>; <xref ref-type="bibr" rid="bib85">Rutar et al., 2012</xref>; <xref ref-type="bibr" rid="bib116">Yang et al., 2011</xref>; <xref ref-type="bibr" rid="bib81">Raoul et al., 2010</xref>; <xref ref-type="bibr" rid="bib69">Nakamura et al., 2015</xref>; <xref ref-type="bibr" rid="bib108">Wang et al., 2019</xref>). Moreover, modulating macrophage activation has been shown to alter photoreceptor cell survival both in Ccl2/Cx3cr1 double-knockout mice (<xref ref-type="bibr" rid="bib95">Shen et al., 2011</xref>) and in a model of photic injury (<xref ref-type="bibr" rid="bib74">Ni et al., 2008</xref>).</p><p>Upon infiltration, monocytes can differentiate into a variety of macrophage phenotypes. Although these phenotypes can have high plasticity and heterogeneity, two primary subtypes of macrophages—namely, M1 and M2 macrophages—represent opposite extremes of the polarization spectrum (<xref ref-type="bibr" rid="bib55">Mantovani et al., 2002</xref>; <xref ref-type="bibr" rid="bib58">Martinez et al., 2008</xref>). M1 macrophages are generally considered to be pro-inflammatory (<xref ref-type="bibr" rid="bib56">Mantovani et al., 2004</xref>; <xref ref-type="bibr" rid="bib97">Sica et al., 2014</xref>), while M2 macrophages are generally associated with tissue repair and remodeling (<xref ref-type="bibr" rid="bib60">Martinez and Gordon, 2014</xref>; <xref ref-type="bibr" rid="bib67">Mills, 2012</xref>). Interestingly, however, studies suggest that this functional dichotomy between M1 and M2 macrophages may not accurately reflect the plasticity of macrophage activity (<xref ref-type="bibr" rid="bib41">Hu et al., 2014</xref>). In addition, other studies suggest that a variety of factors such as age (<xref ref-type="bibr" rid="bib122">Zhao et al., 2013</xref>; <xref ref-type="bibr" rid="bib89">Sebastián et al., 2009</xref>; <xref ref-type="bibr" rid="bib46">Kelly et al., 2007</xref>; <xref ref-type="bibr" rid="bib92">Sene et al., 2013</xref>), genetic background (<xref ref-type="bibr" rid="bib106">Tuo et al., 2012</xref>), the tissue/organ involved, and the presence of underlying disease (<xref ref-type="bibr" rid="bib50">Lewis and Pollard, 2006</xref>) can differentially affect both the function and response of macrophages. In the context of AMD, we previously showed that human monocyte-derived macrophages (hMdɸs) obtained from patients with AMD have a stronger pro-angiogenic effect than hMdɸs obtained from age-matched controls (<xref ref-type="bibr" rid="bib39">Hagbi-Levi et al., 2017</xref>).</p><p>Specific chemokine receptors have also been implicated in AMD. For example, monocytes expressing CCR2 (C-C chemokine receptor type 2) have been found in the vicinity of geographic atrophy lesions, suggesting a pathogenic role (<xref ref-type="bibr" rid="bib93">Sennlaub et al., 2013</xref>). However, which macrophage subtype is associated with cell death and/or the beneficial effects of drusen degradation in preventing RPE cell loss is currently unknown. Interestingly, CCR3 has been implicated in angiogenesis (<xref ref-type="bibr" rid="bib94">Sharma et al., 2013</xref>), and CX3CR1 (C-X3-C motif chemokine receptor 1) has been implicated in the activation of microglial cells (<xref ref-type="bibr" rid="bib20">Combadière et al., 2007</xref>).</p><p>CCR1, a G protein-coupled receptor, has been shown to play an essential role in recruiting leukocytes during inflammation (<xref ref-type="bibr" rid="bib105">Tsou et al., 1998</xref>), and this receptor is expressed in a variety of immune cell types, including dendritic cells, neutrophils, T cells, and monocytes/macrophages (<xref ref-type="bibr" rid="bib40">Horuk, 2001</xref>; <xref ref-type="bibr" rid="bib33">Gao et al., 1997</xref>). We previously showed that monocytes obtained from a patient with AMD had increased expression of both CCR1 and CCR2 compared to monocytes obtained from an age-matched control (<xref ref-type="bibr" rid="bib37">Grunin et al., 2012</xref>). Although CCR1 has been implicated in renal ischemia (<xref ref-type="bibr" rid="bib30">Furuichi et al., 2008</xref>), rheumatoid arthritis (<xref ref-type="bibr" rid="bib88">Santella et al., 2014</xref>; <xref ref-type="bibr" rid="bib71">Nanki, 2016</xref>), endometriosis (<xref ref-type="bibr" rid="bib114">Xu et al., 2014</xref>; <xref ref-type="bibr" rid="bib104">Trummer et al., 2017</xref>; <xref ref-type="bibr" rid="bib117">Yang et al., 2013</xref>), and multiple sclerosis, its role in AMD remains unknown.</p><p>Here, we investigated the signaling pathway involved in macrophage-mediated photoreceptor cell death, and we examined whether targeting macrophage signaling may serve as a potential therapeutic strategy for AMD.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>M2a hMdɸs increase photic-induced photoreceptor degeneration</title><p>We first compared the effect of monocytes from AMD and healthy individual on photoreceptor cells subjected to neurodegenerative conditions. To induce neurodegeneration, mice were exposed to bright light (photic retinal injury; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Light exposure caused photoreceptor cell death around the optic nerve head (ONH) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B, C</xref>), while cells in the periphery were mostly spared (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D, E</xref>). Immediately after photic injury, the mice received an intravitreal injection of human monocytes derived from patients with AMD in one eye; the fellow eye was injected with human monocytes derived from unaffected age-matched controls. Eyes injected with monocytes from unaffected controls showed reduced electroretinography (ERG) b-wave amplitudes at various light stimuli intensities compared with eyes injected with monocytes from AMD patients (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref>). This finding is supported by previous studies showing diminished functionality and plasticity of monocyte/macrophages from unhealthy patients, and particularly AMD, compared with controls (<xref ref-type="bibr" rid="bib38">Gu et al., 2021</xref>). For example, an altered M1/M2 polarization balance (<xref ref-type="bibr" rid="bib21">Costantini et al., 2018</xref>) and change in gene expression profile (<xref ref-type="bibr" rid="bib37">Grunin et al., 2012</xref>) were reported in monocyte/macrophages.</p><p>Thus, the following experiments were focused on monocytes/macrophages derived from AMD patients to obtain a comprehensive understanding of the role of these cells in AMD progression. We examined whether monocytes obtained from AMD patients are neuroprotective or detrimental to photoreceptor cell survival in the photic injury model. Immediately after photic retina injury in mice, human monocytes from AMD patients were delivered via intravitreal injection in one eye; the other eye was injected with vehicle (phosphate-buffered saline [PBS]) as a control (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Compared with the control eyes, eyes injected with monocytes extracted from AMD patients showed reduced ERG b-wave amplitudes at various light intensities (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1I</xref>), and increased photoreceptor cell loss in the dorso-central retina at distance ranging from –300 to –1200 µm from the ONH (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1J</xref>).</p><p>Once recruited to the site of inflammation, monocytes can differentiate into variety of macrophage subtypes; we therefore evaluated for correlation between macrophage polarization and the neurotoxicity observed in the photic-injured retina. To that end, monocytes obtained from patients with AMD were polarized into M0, M1, M2a, and M2c macrophages by stimulation with M-CSF, LPS+IFNγ, IL-4+IL-13, or IL-10, respectively. Polarization of M0 macrophages into the appropriate activated hMdɸs was confirmed using qPCR to measure <italic>CXCL10</italic> (a marker of M1 hMdɸs) (<xref ref-type="bibr" rid="bib120">Yuan et al., 2015</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>), <italic>CCL17</italic> (a marker of M2a hMdɸs) (<xref ref-type="bibr" rid="bib39">Hagbi-Levi et al., 2017</xref>; <xref ref-type="bibr" rid="bib55">Mantovani et al., 2002</xref>; <xref ref-type="fig" rid="fig1">Figure 1B</xref>), and <italic>CD163</italic> (a marker of M2c hMdɸs) (<xref ref-type="bibr" rid="bib120">Yuan et al., 2015</xref>; <xref ref-type="fig" rid="fig1">Figure 1C</xref>). In addition, each hMdɸ subtype displayed a distinct morphology (<xref ref-type="fig" rid="fig1">Figure 1D–G</xref>). Polarization into M1 and M2a hMdɸs was also validated by immunohistochemistry for CD80 and CD206, respectively (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A, B</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>In vitro characterization of hMdɸs and in vivo cytotoxicity of M2a hMdɸ cells.</title><p>(<bold>A–C</bold>) Human M0 macrophages (hMdɸs) were polarized to form M1, M2a, or M2c hMdɸs, and expression of the phenotype-specific markers CXCL10 (<bold>A</bold>), CCL17 (<bold>B</bold>), and CD163 (<bold>C</bold>), respectively, was confirmed using quantitative real-time PCR (n=5 per group, one-way ANOVA with multiple comparisons). (<bold>D–G</bold>) Inverted phase-contrast microscopy of M0 (<bold>D</bold>), M1 (<bold>E</bold>), M2a (<bold>F</bold>), and M2c (<bold>G</bold>) hMdɸs, showing distinct morphologies for each subtype. (<bold>H–K</bold>) Relative electroretinography (ERG) b-wave amplitude versus light flash intensity of mice injected with M0 (<bold>H</bold>), M1 (<bold>I</bold>), M2a (<bold>J</bold>), and M2c (<bold>K</bold>) hMdɸs and control mice that were not exposed to light; ERG recordings revealed that adoptive transfer of M2a hMdɸs—but no other macrophage phenotypes—lead to suppressed b-wave amplitude (n=8 mice for each group, one-way ANOVA with multiple comparisons). The relative ERG b-wave was calculated by dividing the b-wave amplitude recorded from the mouse eye injected with hMdɸs by the b-wave amplitude recorder from the vehicle-injected eye of the same mouse. Similar b-wave amplitudes were recorded in fellow eyes of control mice. (<bold>L–N</bold>) Representative ERG recordings in control mice and in photic-injured mice in which the right eye (RE) was injected with M1(<bold>M</bold>) or M2a (<bold>N</bold>) hMdɸs and the left eye (LE) was injected with phosphate-buffered saline (PBS) as vehicle. ‘a’ and ‘b’ in the graph indicate the a-wave and the b-wave of the ERG, respectively. (<bold>O–R</bold>) Summary of the relative number of photoreceptor nuclei in the ONL measured at the indicated distances from the optic nerve head. A decrease in the number of photoreceptors nuclei was observed after adoptive transfer of M2a hMdɸ (<bold>Q</bold>), but not of other macrophage subtypes (<bold>O, P, and R</bold>) (n=8 mice for each group, one-way ANOVA with multiple comparisons). The relative number of photoreceptor nuclei was calculated by comparing the number of photoreceptor nuclei present in the ONL of the mouse eye injected with hMdɸ and the counterpart vehicle-injected eye. (<bold>S–U</bold>) Representative immunofluorescence images of retinal slices prepared from the indicated mice following an injection of DiO-stained hMdɸs (green); the nuclei were counterstained with DAPI (blue), and the ONL is indicated (red brackets). Note the presence of DiO-positive M2a hMdɸs in the GCL (<bold>U</bold>). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Data shown as mean ± SEM. p-Values indicated by *p&lt;0.05 and **p&lt;0.01. Scale bars: 50 µm (<bold>D–G and S–U</bold>).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Real-time quantitative PCR (qPCR) analysis of <italic>CXCL10</italic>, <italic>CCL17</italic>, and <italic>CD163</italic> mRNA in M0, M1, M2a, and M2c macrophages derived from human monocytes (hMdɸs).</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81208-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Electroretinography (ERG) b-wave recordings and outer nuclear layer (ONL) thickness of hMdɸs-treated mice and untreated mice.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81208-fig1-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81208-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Establishing a model of photic retinal damage.</title><p>(<bold>A</bold>) Schematic diagram depicting the experimental design. The mice in the treated group underwent photic injury followed by an intravitreal injection of hMdɸs in the right eye (RE) and vehicle (phosphate-buffered saline [PBS]) in the left eye (LE); control mice were not exposed to photic injury, nor did they receive intravitreal injections. Fellow eyes in the treated and control mice were measured electroretinography (ERG) 7 days after photic injury, and thickness of the outer nuclear layer (ONL) was measured using histology 8 days after photic injury. (<bold>B–E</bold>) TUNEL (red) and DAPI (blue) staining of BALB/c mouse retinas 2 days after photic injury shows apoptotic photoreceptor cells (asterisk) and retinal pigment epithelial (RPE) cells (arrow) in the posterior retina (<bold>B and C</bold>), and relatively few apoptotic cells (arrow) in the peripheral retina (<bold>D and E</bold>). (<bold>F–G</bold>) Optical coherence tomography images obtained 7 days after photic injury reveal a marked reduction in ONL thickness (red asterisks) in a treated mouse (<bold>G</bold>) compared to a control mouse (<bold>F</bold>); 1, 2, and 3 indicate the ganglion cell layer (GCL), inner nuclear layer (INL), and ONL, respectively. (<bold>H</bold>) Relative b-wave ERG amplitudes versus flash intensity recorded from mice eyes injected with monocytes from aged-matched controls vs. monocytes from age-related macular degeneration (AMD) patients (n=9) and control mice that were not exposed to light (n=9). Suppressed b-wave amplitude was observed in the eyes injected with monocytes from healthy individuals compared with eyes injected with monocytes from AMD patients (Student’s t-test). (<bold>I</bold>) Relative b-wave ERG amplitudes versus flash intensity recorded from mice injected with monocytes (n=7) and control mice that were not exposed to light (n=9). Suppressed b-wave amplitude was observed in the eyes injected with monocytes (Student’s t-test). (<bold>J</bold>) A reduced number of photoreceptor nuclei were found in eyes injected with monocytes from AMD patients at different distances from the optic nerve head (ONH) (Student’s t-test). (<bold>K–S</bold>) Human monocyte polarization following adoptive transfer to mice eyes with photic-induced retinal injury showed monocytes from AMD patient (Dio-traced, green signal, <bold>K and P</bold>) expresses CD206 and vascular endothelial growth factor (VEGF) (red signal, <bold>L and Q</bold>) confirming polarization toward M2a phenotype. Note that expression of M2a markers were found only upon migration into retinal layers (red arrows in M, R and in high magnitude in O and S), but not in monocytes present in the vitreous (red arrowheads in M, R and in high magnitude in N). Data shown as mean ± SEM. p-Values indicated by *p&lt;0.05 and **p&lt;0.01. Scale bars: 20 µm (<bold>N,O,S</bold>), 50 µm (<bold>B–E, K–M, P–R</bold>), and 200 µm (<bold>F and G</bold>).</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Electroretinography (ERG) b-wave recordings and outer nuclear layer (ONL) thickness of monocytes-treated mice and untreated mice.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81208-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81208-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Adoptive transfer of M2a hMdɸ cells into mouse eyes.</title><p>(<bold>A–B</bold>) Polarized M1 (<bold>A</bold>) and M2a (<bold>B</bold>) hMdɸs obtained from patients with age-related macular degeneration (AMD), showing distinct morphological differences and CD80 (red) or CD206 (red) expression in M1 or M2a hMdɸs respectively; the nuclei were counterstained with DAPI (blue). (<bold>C–H</bold>) Inverted phase-contrast microscopy images of cryosections prepared from mouse eyes 7 days after photic retinal injury and intravitreal injection of DiO-labeled M2a hMdɸs, showing M2a hMdɸs in the vitreous (<bold>C</bold>) with a polarized profile and elongated cell morphology (<bold>D</bold>), as well as across the layers of the retina (G, asterisk), including the subretinal space (G, arrows). Also, M0 (<bold>E</bold>), M1 (<bold>F</bold>), and M2c (<bold>H</bold>) hMdɸs were reached the different retinal layers. (<bold>I–L</bold>) Retinal flat-mount (<bold>I, K</bold>) and fundus autofluorescence images (<bold>J, L</bold>) of the retina 7 days after injecting M2a hMdɸs. Note the migration of M2a hMdɸs toward the ONH (the red cross in <bold>I and J</bold>) and in the vicinity of the large retinal vessels (arrows in <bold>I and J</bold>); also note the high density of M2a hMdɸs in the superior retinal area (indicated by the rectangles in <bold>K and L</bold>). S, superior; I, inferior; T temporal; N, nasal; GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; ONH, optic nerve head. Scale bars: 50 µm (<bold>A, B, D, and E–H</bold>), 100 µm (<bold>I and K</bold>), and 200 µm (<bold>C</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81208-fig1-figsupp2-v1.tif"/></fig></fig-group><p>When we tested the effects of polarized hMdɸs in our photic retinal injury model, we found that M2a hMdɸs suppressed ERG b-wave amplitude at various light intensities (<xref ref-type="fig" rid="fig1">Figure 1J and N</xref>) and accelerated photoreceptor cell loss from –300 µm to –1200 µm from the ONH (<xref ref-type="fig" rid="fig1">Figure 1Q and U</xref>) compared to control eyes. In contrast, M1 hMdɸs, which have been reported as pro-inflammatory cells in other organs (<xref ref-type="bibr" rid="bib23">Cruz-Guilloty et al., 2013</xref>), had no effect on ERG b-wave amplitude or outer nuclear layer (ONL) thinning compared to control eyes (<xref ref-type="fig" rid="fig1">Figure 1I and P</xref>). Similarly, neither M2c hMdɸs nor M0 hMdɸs affected photoreceptor cell death (<xref ref-type="fig" rid="fig1">Figure 1H, K, O, R</xref>).</p><p>Immunohistochemistry for VEGF and CD206 (mannose), both accepted as M2a markers (<xref ref-type="bibr" rid="bib45">Kadomoto et al., 2021</xref>; <xref ref-type="bibr" rid="bib13">Brüne et al., 2015</xref>), demonstrated that monocytes from AMD patients polarized into M2a phenotypes following delivery to the mice eye in the photic retina injury model (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1K–S</xref>). This finding may explain why monocytes from healthy individuals showed higher neurotoxicity compared with monocytes from AMD patients. Our previous research (<xref ref-type="bibr" rid="bib39">Hagbi-Levi et al., 2017</xref>) indicated that M2a hMdɸs from healthy individual were associated with increased expression and secretion of pro-inflammatory proteins such as IL-6, CCL2, SDF-1, VEGF, and PDGF-α, compared with M2a hMdɸs from AMD patients. Together, these results support the existence of a variable effect of monocytes/macrophages function, especially concerning M2a macrophages, between individuals affected by AMD and unaffected individuals.</p><p>In an attempt to explain the increased death of photoreceptors in the dorso-central retina following injection of M2a hMdɸs, after inducing photic injury we monitored the spatial distribution of the injected cells for 7 days using histology. We identified the injected M2a hMdɸs by their typical elongated cell shape (<xref ref-type="bibr" rid="bib39">Hagbi-Levi et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">McWhorter et al., 2013</xref>) and the Dio tracer (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B, D</xref>). Although most of the injected M2a hMdɸs were scattered throughout the vitreous (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>), several of these cells migrated across the retina layers, reaching the subretinal space (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2G</xref>), with many hMdɸ cells present around the ONH and along the retinal vessels (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2I, J</xref>). A similar pattern of distribution was observed in eyes injected with the other types of hMdɸs (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E, F and H</xref>), indicating that the detrimental effect attributed to M2a phenotype was not related to its migration capacity.</p><p>Histological analysis revealed that the deleterious effects of M2a hMdɸs occurred primarily in the dorso-central region ranging at distances of –300 µm to –1200 µm from the ONH (<xref ref-type="fig" rid="fig1">Figure 1Q</xref>). A retinal flat-mount analysis and in vivo fundus autofluorescence confirmed that the injected M2a hMdɸs were found primarily in the superior half of the eye, corresponding to the area of photoreceptor cell death (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2K, L</xref>).</p></sec><sec id="s2-2"><title>M2a hMdɸs have a neurotoxic effect on retinal tissue ex vivo</title><p>Our in vivo experiments showed that M1 hMdɸs did not induce neurotoxicity, whereas M2a hMdɸs had a robust neurotoxic effect. To support these in vivo findings, we compared the effect of M1 and M2a hMdɸs ex vivo by co-culturing retinal explants with 10<sup>5</sup> cells for 18 hr, followed by TUNEL staining. We measured the number of apoptotic photoreceptor cells in the retinal explants using confocal microscopy (<xref ref-type="fig" rid="fig2">Figure 2A–C</xref>), and we performed cell sorting (<xref ref-type="fig" rid="fig2">Figure 2D–G</xref>). We found that explants co-cultured with M2a hMdɸs had significantly more apoptotic photoreceptor cells compared to both control retinal explants (without co-cultured macrophages) and explants co-cultured with M1 hMdɸs (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). We then determined the cell types that were affected by the M2a macrophages in the retinal explants and in choroid-RPE explants that were co-cultured with M2a hMdɸs, revealing photoreceptor cell death (<xref ref-type="fig" rid="fig2">Figure 2I</xref>) and RPE cell death (<xref ref-type="fig" rid="fig2">Figure 2J and K</xref>), respectively.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>M2a hMdɸs have neurotoxic effects on retinal explants.</title><p>(<bold>A–C</bold>) TUNEL staining (red) of mouse retinal explants co-cultured with either M1 hMdɸs (<bold>B</bold>) or M2a hMdɸs (<bold>C</bold>) for 18 hr; the nuclei were counterstained with DAPI (blue). Confocal microscopy assessment of 11 randomly selected retinal fields (<bold>A</bold>) revealed M2a hMdɸ (<bold>C</bold>) to be associated with photoreceptor cell apoptosis as compared to M1 hMdɸ. (<bold>D–G</bold>) Representative FACS gating plot of cells obtained from the indicated retinal explants stained using TUNEL-PE; TUNEL<sup>+</sup> cells are shown in the red rectangles based on an unstained retinal explant. (<bold>H</bold>) Summary of the percentage of apoptotic (TUNEL<sup>+</sup>) cells measured in control explants and in explants that were co-cultured with M1 or M2a hMdɸs (n=6 per group, one-way ANOVA with multiple comparisons). (<bold>I</bold>) Rhodopsin immunostaining (green) of a retinal explant showing the association of macrophages with apoptotic photoreceptor cells, indicated by the co-localization of TUNEL and rhodopsin staining in a <italic>Z</italic>-stack (arrow). (<bold>J–K</bold>) Co-culturing retinal pigment epithelial (RPE)-choroid explants with M2a hMdɸs results in the co-localization of TUNEL staining (red) and the RPE marker RPE65 marker (J; green), as well as the presence of TUNEL-positive hexagonal and pigmented cells (K; arrows). (<bold>L</bold>) The addition of supernatant collected from M2a hMdɸs to retinal explants increased photoreceptor death (measured as an increase in the percentage of TUNEL-positive cells) (n=6 per group, one-way ANOVA with multiple comparisons). INL, inner nuclear layer; ONL, outer nuclear layer. Data shown as mean ± SEM. p-Values indicated by *p&lt;0.05. Scale bars: 20 µm (<bold>G and H</bold>), 50 µm (<bold>B, C, and F</bold>), and 200 µm (<bold>A</bold>).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Summary of the percentage of apoptotic (TUNEL<sup>+</sup>) cells measured in the different groups of retinal explant.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81208-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81208-fig2-v1.tif"/></fig><p>Although the injected M2a hMdɸs were observed in different retinal layers in our in vivo experiments, it is also possible that mediators released from these hMdɸs—and not necessarily direct contact with the macrophages themselves—contributed to the increase in photoreceptor cell death. To determine whether direct contact between M2a hMdɸs and photoreceptor cells is required for inducing apoptosis, we examined retinal explants that were treated with cell-free hMdɸ-conditioned medium. We found that retinal explants cultured with supernatant from M2a hMdɸs had significantly increased cell death; in contrast, culturing explants with supernatant from M1 hMdɸs had no effect (<xref ref-type="fig" rid="fig2">Figure 2L</xref>). Interestingly, retinal explants co-incubated with M2a hMdɸ cells had a higher percentage of apoptosis (10%; <xref ref-type="fig" rid="fig2">Figure 2H</xref>) compared to explants incubated with M2a hMdɸ-conditioned medium (3%; p=0.028; <xref ref-type="fig" rid="fig2">Figure 2L</xref>). These ex vivo results suggest that M2a hMdɸ cells have the capacity to directly affect neuronal tissues independent of the systemic inflammatory context and without the need to recruit additional cell types.</p></sec><sec id="s2-3"><title>Characterization of the neurotoxic properties of M2a hMdɸs</title><p>Next, we attempted to characterize the putative neurotoxic effects of M2a hMdɸs on photoreceptor cells. Macrophages are a potential source of reactive oxygen species (ROS), and oxidative stress has been implicated in the progression of various retinal diseases, including AMD (<xref ref-type="bibr" rid="bib8">Beatty et al., 2000</xref>). To explore the role of ROS production in M2a hMdɸ-mediated neurotoxicity, we measured in vitro ROS production in M0, M1, and M2a hMdɸs and found that M2a hMdɸs release significantly more ROS compared to both M0 and M1 hMdɸs (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We also used hydroxynonenal (HNE) staining to evaluate the oxidative damage in a retinal section following photic injury and found that injection of either M1 or M2a hMdɸs was not associated with increased oxidative damage compared to control conditions (<xref ref-type="fig" rid="fig3">Figure 3B, C and D</xref>). Exposing retina to strong light (such as in photic retinal injury) leads to the ROS production due to exacerbated action of the visual cycle (<xref ref-type="bibr" rid="bib75">Ozawa, 2020</xref>). Thus, the additional limited contribution of ROS production by M2a hMdɸs in photic injured retina may be difficult to detect. Together, these data suggest that M2a hMdɸ-mediated neurotoxicity may be partially also driven by increased ROS release from these cells, although further investigations are required to confirm this possibility.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>M2a hMdɸs produce high levels of reactive oxygen species (ROS) and induce the infiltration of cd11b<sup>+</sup> cells.</title><p>(<bold>A</bold>) Cultured M2a hMdɸs produce higher levels of ROS than both M0 and M1 hMdɸs; ROS production was measured using the DCFDA fluorogenic dye (n=5 per group, one-way ANOVA with multiple comparisons). (<bold>B–C</bold>) Hydroxynonenal (HNE) immunostaining (green) shows similar levels of oxidative stress in mouse eyes following an intravitreal injection of either M1 hMdɸs (<bold>B</bold>) or M2a hMdɸs (<bold>C</bold>). (<bold>D</bold>) Summary of relative oxidative stress levels measured in control eyes and in eyes injected with M1 or M2a hMdɸs calculated by comparing the fluorescence level of HNE-stained sections of the hMdɸ-injected eye and the vehicle-injected eye of the same mouse. HNE staining intensity was quantified using ImageJ (n=7 per group, one-way ANOVA with multiple comparisons). (<bold>E–H</bold>) cd11b immunostaining (red, arrows) shows an increased presence of mononuclear phagocytes in the choroid tissue following photic injury (<bold>F</bold>) and in eyes following an intravitreal injection of M1 hMdɸs (<bold>G</bold>) or M2a hMdɸs (<bold>H</bold>). (<bold>I</bold>) Summary of cd11b<sup>+</sup> cells present in the choroid tissue in eyes following an intravitreal injection of M1 or M2a hMdɸs (n=7 per group, Student’s t-test). (<bold>J–K</bold>) Inverted phase-contrast microscopy images of the optic nerve head (ONH) showing the migration of DiO-labeled M2a hMdɸ cells (K; green) and co-localization with recruited cd11b<sup>+</sup> cells (J; red), shown in the rectangles. (<bold>L</bold>) An in vitro migration assay was performed using a Boyden chamber, showing an increase in monocytes that migrated toward the M2a hMdɸs compared with the M1 hMdɸs (n=6 per group, Student’s t-test). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Data shown as mean ± SEM. p-Values indicated by ns, nonsignificant, *p&lt;0.05. Scale bars: 50 µm (<bold>B–C and E–H</bold>) and 100 µm (<bold>J–K</bold>).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Comparative analysis of reactive oxygen species (ROS) production, fluorescence level of hydroxynonenal (HNE)-stained sections, cd11b-positive cells quantification, and in vitro migration level between M1 and M2a hMdɸs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81208-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81208-fig3-v1.tif"/></fig><p>Although the ex vivo results obtained from our retinal explant experiments suggest that M2a hMdɸs exert a direct neurotoxic effect, additional indirect processes may also contribute to this effect in vivo. For example, the presence of M2a hMdɸs may drive the recruitment of mononuclear cells to the retina, and these cells may exert an additional neurotoxic effect. To examine this possibility, we measured cells expressing cd11b—a broadly expressed integrin that serves as a marker of mononuclear phagocytes—in the choroid of photic-injured mice following an injection of either M1 or M2a hMdɸs. We found that injecting M2a hMdɸs led to significantly more recruitment of cd11b<sup>+</sup> cells to the choroid compared to injecting M1 hMdɸs (<xref ref-type="fig" rid="fig3">Figure 3G–I</xref>). In addition, we found that M2a hMdɸs and cd11b<sup>+</sup> cells were co-localized across the ONH, suggesting the existence of crosstalk between these two cell types (<xref ref-type="fig" rid="fig3">Figure 3J and K</xref>).</p><p>In principle, an inflammatory response may have potentially resulted from the xenograft; however, the eye is an immune-privileged site, and we previously excluded the possibility that adoptive transfer of hMdɸs causes a cross-species reaction (<xref ref-type="bibr" rid="bib39">Hagbi-Levi et al., 2017</xref>). In addition, we tested all four hMdɸ subtypes in our xenograft model but found that only M2a hMdɸs were associated with an increased recruitment of endogenous cells. To confirm that cd11b<sup>+</sup> cells are indeed recruited specifically by M2a hMdɸs, we measured the in vitro chemotactic capacity of M1 and M2a hMdɸs on freshly isolated human monocytes. Using FACS analysis, we found that chemokines released from M2a hMdɸs attracted more monocytes compared to chemokines released from M1 hMdɸs (<xref ref-type="fig" rid="fig3">Figure 3L</xref>). Taken together, these results indicate that M2a hMdɸs differ from the M1 hMdɸs phenotypes with respect to their capacity to recruit additional immune cells to the site of injury and their ability to increase oxidative stress, thereby exacerbating photoreceptor cell death in the context of inflammation.</p></sec><sec id="s2-4"><title>CCR1 expression and apoptosis are increased in the retina following photic-induced damage</title><p>Next, we examined whether a cytokine-mediated interaction between M2a hMdɸs and the retinal environment underlies photoreceptor cell death. Using a multiplex cytokine array, we compared the levels of 120 cytokines (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) between M1 hMdɸ-conditioned medium and M2a hMdɸ-conditioned medium (n=6 per group, Student’s t-test).</p><p>We found that 9 cytokines were significantly higher in the M2a hMdɸ-conditioned medium, while 15 cytokines were significantly higher in the M1 hMdɸ-conditioned medium (Table 2). Several of the 9 cytokines that were increased in the M2a hMdɸ-conditioned medium were previously reported to play a role in various inflammatory processes, including ocular inflammatory diseases and neurodegenerative diseases; these cytokines include CCL11 (<xref ref-type="bibr" rid="bib25">Deng et al., 2019</xref>; <xref ref-type="bibr" rid="bib68">Mor et al., 2019</xref>; <xref ref-type="bibr" rid="bib91">Segal-Salto et al., 2020</xref>; <xref ref-type="bibr" rid="bib96">Shoji et al., 2017</xref>; <xref ref-type="bibr" rid="bib121">Zeng et al., 2019</xref>), CCL13 (<xref ref-type="bibr" rid="bib26">El-asrar et al., 2019</xref>; <xref ref-type="bibr" rid="bib66">Méndez-Enríquez et al., 2014</xref>; <xref ref-type="bibr" rid="bib65">Mendez-Enriquez and García-Zepeda, 2013</xref>; <xref ref-type="bibr" rid="bib121">Zeng et al., 2019</xref>), CCL17 (<xref ref-type="bibr" rid="bib24">Dai et al., 2015</xref>; <xref ref-type="bibr" rid="bib119">Yu et al., 2011</xref>; <xref ref-type="bibr" rid="bib121">Zeng et al., 2019</xref>), CCL23 (<xref ref-type="bibr" rid="bib28">Faura et al., 2020</xref>; <xref ref-type="bibr" rid="bib98">Simats et al., 2018</xref>; <xref ref-type="bibr" rid="bib121">Zeng et al., 2019</xref>), and CCL14 (<xref ref-type="bibr" rid="bib52">Liu et al., 2016</xref>).</p><p>Interestingly, three of these cytokines (CCL14, CCL13, and CCL23) are ligands of the C-C chemokine receptor CCR1. To confirm these multiplex ELISA results, we performed real-time quantitative PCR (qPCR) analysis of the mRNAs that encode these three CCR1 ligands and found significantly higher levels of both <italic>CCL23</italic> and <italic>CCL13</italic> mRNA in M2a hMdɸs compared to M1 hMdɸs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A, B</xref>); in contrast, we found no significant difference in <italic>CCL14</italic> mRNA levels between M2a and M1 hMdɸs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>).</p><p>Next, we attempted to identify which cell type(s) in the retina express CCR1 and are therefore affected by the cytokines released by M2a hMdɸs and drive photoreceptor cell death in response to photic-induced injury. Using immunofluorescence, we found increased levels of CCR1 protein in the mouse retina—primarily in the ONL— 48 hr after inducing photic injury (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). We also measured robust CCR1 immunofluorescence in the inner nuclear layer (INL) and inner plexiform layer (IPL) 7 days after photic injury (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). We then performed dual immunostaining for CCR1 and the glial cell marker GFAP in retinal sections and found strong co-localization of these two proteins following photic injury (<xref ref-type="fig" rid="fig4">Figure 4K</xref>). These results indicate that CCR1 is expressed primarily in Müller cells, the only retinal cell type that spans all of the layers of the retina (<xref ref-type="bibr" rid="bib11">Bringmann et al., 2006</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>CCR1 is upregulated in a mouse model of photic injury.</title><p>(<bold>A–F</bold>) Albino BALB/c mice were exposed to photic injury; 48 hr and 7 days later, retinal sections were prepared and immunostained for Ccr1 (A–C; red) or TUNEL stained (D–F, red); the nuclei were counterstained with DAPI (blue). (<bold>G</bold>) Real-time quantitative PCR (qPCR) analysis of retinal <italic>Ccr1</italic> mRNA measured in control mice and in mice 7 days after photic injury (n=6 mice for each group, Student’s t-test). (<bold>H</bold>) <italic>Ccr1</italic> expression plotted against the b-wave amplitude measured using electroretinography (ERG) in mice 7 days after photic injury. Each symbol represents an individual mouse eye, and the correlation coefficient and p-value are shown. (<bold>I–K</bold>) Retinal sections were prepared 7 days after photic injury and co-immunostained for CCR1 (I; red) and the glial cell marker GFAP (J; green); the nuclei were counterstained with DAPI (blue). GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer. Data shown as mean ± SEM. p-Values indicated by **p&lt;0.005. Scale bars: 50 µm (A–F and I–K).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Real-time quantitative PCR (qPCR) analysis of retinal <italic>Ccr1</italic> mRNA in control mice vs. photic-injured mice and the correlation between the <italic>Ccr1</italic> expression and the electroretinography (ERG) b-wave amplitude.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81208-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81208-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Two CCR1 ligands are expressed at higher levels in M2a hMdɸs compared to M1 hMdɸs.</title><p>(<bold>A–C</bold>) Real-time quantitative PCR (qPCR) analysis of <italic>CCL23</italic> (<bold>A</bold>), <italic>CCL13</italic> (<bold>B</bold>), and <italic>CCL14</italic> (<bold>C</bold>) mRNA in M1 and M2a macrophages derived from human monocytes (n=6 per group, Student’s t-test). Data shown as mean ± SEM. p-Values indicated by ns, nonsignificant, *p&lt;0.05.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Real-time quantitative PCR (qPCR) analysis of <italic>CCL23</italic>, <italic>CCL13</italic>, and <italic>CCL14</italic> mRNA in M1 and M2a macrophages derived from human monocytes.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81208-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81208-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Expression of CCR2 and CCR5 in the mouse retina following photic injury.</title><p>(<bold>A–D</bold>) Retinal sections obtained from control and photic-injured mice were immunostained for CCR2 (<bold>A–B</bold>) or CCR5 (<bold>C–D</bold>); the nuclei were counterstained with DAPI (blue). (<bold>E–G</bold>) Flat-mount retinal sections were prepared from photic-injured mice and show recruited cells expressing CCR1 (E; arrows), CCR2 (F; arrows), and CCR5 (G; arrows). (<bold>H–I</bold>) Real-time quantitative PCR (qPCR) analysis of retinal <italic>Ccr2</italic> and <italic>Ccr5</italic> mRNA measured in control mice and photic-injured mice (n=6 mice for each group, Student’s t-test). (<bold>J–L</bold>) Retinal sections obtained from 3-week-old rd10 mice were immunostained for CCR2 (<bold>J</bold>) or CCR5 (<bold>K</bold>); the nuclei were counterstained with DAPI (L; blue). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Data shown as mean ± SEM. p-Values indicated by *p&lt;0.05. Scale bars: 50 µm (<bold>A–D and J–L</bold>) and 20 µm (<bold>E–G</bold>).</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Real-time quantitative PCR (qPCR) analysis of retinal <italic>Ccr2</italic> and <italic>Ccr5</italic> mRNA measured in control mice and photic-injured mice.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81208-fig4-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81208-fig4-figsupp2-v1.tif"/></fig></fig-group><p>Using TUNEL staining, we found a large number of apoptotic photoreceptor cells 48 hr after photic injury (<xref ref-type="fig" rid="fig4">Figure 4E</xref>); 7 days after photic injury, apoptotic photoreceptor cells were still present (<xref ref-type="fig" rid="fig4">Figure 4F</xref>), albeit it to a lesser extent as previously reported (<xref ref-type="bibr" rid="bib42">Jiao et al., 2015</xref>). To confirm that photic injury increases the expression of CCR1 in the retina, we measured <italic>Ccr1</italic> mRNA using qPCR 7 days after photic injury and found significantly increased retinal expression of <italic>Ccr1</italic> compared to control mice (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). We also measured retinal function using ERG recordings and found a strong inverse correlation between retinal <italic>Ccr1</italic> mRNA levels and b-wave amplitude following photic injury (<xref ref-type="fig" rid="fig4">Figure 4H</xref>), suggesting that <italic>Ccr1</italic> expression may play a role in determining the extent of retinal damage.</p><p>Previous studies suggest that CCR1, CCR2, and CCR5 may be functionally redundant (<xref ref-type="bibr" rid="bib35">Gladue et al., 2010</xref>). We therefore examined whether photic injury also increases the level of CCR2 and/or CCR5 protein in Müller cells in the mouse retina using immunofluorescence. Interestingly, however, neither CCR2 (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>) nor CCR5 (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>) was detected in these cells in either control or photic-injured mice.</p><p>Consistent with previous reports that photic injury can promote the recruitment of inflammatory cells (<xref ref-type="bibr" rid="bib54">Lückoff et al., 2017</xref>)—particularly macrophages that express CCR1, CCR2, and CCR5 (<xref ref-type="bibr" rid="bib86">Rutar et al., 2015</xref>)—we found that cells expressing CCR1, CCR2, and CCR5 were recruited to the subretinal space in photic-damaged mice (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2E–G</xref>); moreover, we measured increased levels of both <italic>Ccr2</italic> (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2H</xref>) and <italic>Ccr5</italic> (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2I</xref>) mRNA following photic injury. Taken together, these results suggest that the increased expression of CCR2 and CCR5 following photic injury stems primarily from immune cells that were recruited to the site of damage, while the increased expression of CCR1 likely stems from both increased expression in Müller cells and the recruitment of inflammatory cells to the damaged retina.</p></sec><sec id="s2-5"><title>Increased expression of CCR1 in rd10 mice and senescent mice</title><p>Next, we examined whether CCR1 is also upregulated in other models of retinal degeneration. The rd10 mouse is a model of autosomal recessive retinitis pigmentosa in which a mutation in the <italic>Pde6b</italic> gene (which encodes the enzyme phosphodiesterase in rod cells) causes degeneration of photoreceptor cells starting at around postnatal day 18 (<xref ref-type="bibr" rid="bib17">Chang et al., 2002</xref>). At 7 days of age—that is, before the onset of photoreceptor cell apoptosis—we measured extremely low levels of CCR1 in the retina (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). In contrast, we measured significantly higher expression of CCR1 in both the INL and ONL at 3 and 6 weeks of age, together with a reduction in ONL thickness of approximately 50% and 90% at 3 and 6 weeks, respectively (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). Co-staining for CCR1 and GFAP at 3 weeks of age confirmed that the increased expression of CCR1 occurred specifically in Müller cells (<xref ref-type="fig" rid="fig5">Figure 5I</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Ccr1 is upregulated in both rd10 mice and senescent mice.</title><p>(<bold>A–F</bold>) Retinal sections were prepared from 1-week-old (<bold>A, D</bold>), 3-week-old (<bold>B, E</bold>), and 6-week-old (<bold>C, F</bold>) rd10 mice and immunostained for CCR1; the nuclei were counterstained with DAPI. Note the increased expression of CCR1 (arrows) at 3 weeks (<bold>B</bold>) and 6 weeks (<bold>C</bold>), corresponding with reduced ONL thickness (E and F; double-ended arrows). (<bold>G–I</bold>) Retinal sections were prepared from a 3-week-old rd10 mouse and co-immunostained for CCR1 (G; red) and GFAP (H; green); the nuclei were counterstained with DAPI (<bold>I</bold>). Note the co-localization of CCR1 and GFAP in the Müller cells (<bold>I</bold>). (<bold>J</bold>) Real-time quantitative PCR (qPCR) analysis of retinal <italic>Ccr1</italic> mRNA measured in 1-, 3-, and 6-week-old rd10 mice (n=6 mice for each group, one-way ANOVA with multiple comparisons). (<bold>K</bold>) Real-time qPCR analysis of retinal <italic>Ccr2</italic> and <italic>Ccr5</italic> mRNA measured in 1- and 3-week-old rd10 mice (n=4 mice for each group, Student’s t-test). (<bold>L–N</bold>) Retinal sections were prepared from 18-month-old (senescent) mice and co-immunostained for CCR1 (L; red) and GFAP (M; green); the nuclei were counterstained with DAPI. Note the co-localization of CCR1 and GFAP in the Müller cells (N; arrows). (<bold>O</bold>) Real-time qPCR analysis of retinal <italic>Ccr1</italic>, <italic>Ccr2</italic>, and <italic>Ccr5</italic> mRNA measured in young (6-week-old) and senescent (18-month-old) mice (n=8 mice for each group, Student’s t-test). GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer. Data shown as mean ± SEM. p-Values indicated by ns, not significant and *p&lt;0.05. Scale bars: 50 µm (<bold>A–I and L–N</bold>).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Real-time quantitative PCR (qPCR) analysis of retinal <italic>Ccr1</italic>, <italic>Ccr2,</italic> and <italic>Ccr5</italic> mRNA measured in 1-, 3-, 6-week-old rd10 mice, in young (6-week-old) and senescent (18-month-old) mice.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81208-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81208-fig5-v1.tif"/></fig><p>qPCR analysis of <italic>Ccr1</italic> mRNA confirmed the increased expression of CCR1 in rd10 mice at both 3 and 6 weeks of age compared to 1 week (<xref ref-type="fig" rid="fig5">Figure 5J</xref>). Similarly, we also measured increased levels of both <italic>Ccr2</italic> and <italic>Ccr5</italic> mRNA at 3 weeks of age compared to 1 week (<xref ref-type="fig" rid="fig5">Figure 5K</xref>); however, neither CCR2 nor CCR5 was present in Müller cells based on immunohistochemistry (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2J–L</xref>). Together, these results support the notion that CCR1 expressed in Müller cells plays a distinct role in photoreceptor cell death.</p><p>As the name suggests, AMD primarily affects the elderly (<xref ref-type="bibr" rid="bib111">Wong et al., 2014</xref>). Interestingly, we found that 18-month-old wild-type BALB/c mice (i.e., ‘elderly’ or senescent mice) express CCR1 in both the INL and ONL (<xref ref-type="fig" rid="fig5">Figure 5L</xref>), and co-immunostaining for CCR1 and GFAP shows that CCR1 is expressed primarily in Müller cells (<xref ref-type="fig" rid="fig5">Figure 5M and N</xref>). Moreover, qPCR analysis confirmed that senescent mice have increased levels of retinal <italic>Ccr1</italic> mRNA compared to young mice (<xref ref-type="fig" rid="fig5">Figure 5O</xref>); in contrast, we found no difference between senescent and young mice with respect to <italic>Ccr2</italic> or <italic>Ccr5</italic> mRNA levels (<xref ref-type="fig" rid="fig5">Figure 5O</xref>), and immunohistochemistry confirmed that neither CCR2 nor CCR5 is expressed in Müller cells (unpublished observations).</p></sec><sec id="s2-6"><title>Inhibiting CCR1 reduces photic injury-induced retinal damage</title><p>Based on our finding that CCR1 expression is upregulated in the retina in: (i) photic-injured mice, (ii) rd10 mice in parallel with the onset of retinal degeneration, and (iii) senescent mice, we hypothesized that inhibiting this receptor may slow the rate of photoreceptor loss. To test this hypothesis, we injected mice with the CCR1-specific inhibitor BX471 (or vehicle in control mice) immediately after inducing photic injury. BX471 is a non-peptide antagonist that can bind CCR1 and blocks its signal transduction (<xref ref-type="bibr" rid="bib51">Liang et al., 2000</xref>). We found that BX471-treated mice had both a larger b-wave amplitude on ERG (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) and increased ONL thickness compared to vehicle-treated mice (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), suggesting that inhibiting CCR1 can help against photic injury in mice.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Inhibiting CCR1 reduces the effects of photic injury.</title><p>(<bold>A</bold>) Albino BALB/c mice were subjected to photic injury followed by subcutaneous injections of the CCR1 inhibitor BX471 or vehicle for 5 days. Electroretinography (ERG) recordings were then performed, and the amplitude of the b-wave was measured and is plotted against flash intensity (n=12 eyes for each group, Student’s t-test). (<bold>B</bold>) The number of photoreceptor nuclei was measured at the indicated distances from the optic nerve (n=14 eyes for each group, Student’s t-test). (<bold>C–G</bold>) Retinal sections were prepared from vehicle-treated mice (<bold>C</bold>) and BX471-treated mice (<bold>D</bold>) and immunostained for the microglial cell marker IBA-1. The asterisks indicate amoeboid-shaped cells in the ONL and subretinal layer (<bold>C</bold>), and the arrows indicate elongated cells in the GCL and IPL, with one cell shown in a magnified view (D; inset). (<bold>E</bold>) Real-time quantitative PCR (qPCR) analysis of retinal <italic>Adgre1</italic> mRNA (which encodes the macrophage marker F4/80) in control mice, vehicle-treated photic-injured mice, and BX471-treated photic-injured mice (n=6 mice for each group, one-way ANOVA with multiple comparisons). (<bold>F–G</bold>) Retinal sections were prepared from vehicle-treated photic-injured mice (<bold>F</bold>) and BX471-treated photic-injured mice (<bold>G</bold>) and immunostained for CCR1. (<bold>H</bold>) Real-time qPCR analysis of retinal <italic>Ccr1</italic> mRNA measured in vehicle-treated photic-injured mice and BX471-treated photic-injured mice (n=6 mice for each group, Student’s t-test). (<bold>I–K</bold>) Real-time qPCR analysis of retinal <italic>Ccl2</italic> (<bold>I</bold>), <italic>Cxcl1</italic> (<bold>J</bold>), and <italic>Cxcl10</italic> (<bold>K</bold>) mRNA measured in control mice, vehicle-treated photic-injured mice, and BX471-treated photic mice (n=6 mice for each group, one-way ANOVA with multiple comparisons). GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer. Data shown as mean ± SEM. p-Values indicated by ns, not significant and *p&lt;0.05, **p&lt;0.01, <sup>#</sup>p&lt;0.001. Scale bars: 50 µm (<bold>C–D and F–G</bold>) and 20 µm (inset in D).</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Electroretinography (ERG) b-wave recordings and outer nuclear layer (ONL) thickness of vehicle-treated mice and BX471-treated mice.</title><p>Real-time quantitative PCR (qPCR) analysis of retinal <italic>F4/80, Ccr1, Ccl2</italic>, <italic>Cxcl1</italic>, and <italic>Cxcl10</italic> mRNA in control mice, vehicle-treated photic-injured mice, and BX471-treated photic-injured mice.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81208-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81208-fig6-v1.tif"/></fig><p>Interestingly, immunostaining for the protein IBA-1 (ionized calcium-binding adaptor molecule 1, a marker of microglial activation) revealed that photic injury-induced microglial activation was reduced in BX471-treated mice. Specifically, we found that BX471-treated mice photic-injured had elongated microglial cells that were localized primarily to the ganglion cell layer and INL (<xref ref-type="fig" rid="fig6">Figure 6D</xref>); in contrast, vehicle-treated photic-injured mice had amoeboid-shaped microglial cells that infiltrated both the ONL and subretinal space (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Moreover, qPCR analysis revealed that photic injury increased the recruitment of macrophages to the retina (based on increased retinal expression of the macrophage marker F4/80), and this recruitment was significantly reduced in BX471-treated mice (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). We also found that BX471 reduced CCR1 expression in Müller cells in photic-injured mice compared to control-treated mice (<xref ref-type="fig" rid="fig6">Figure 6G</xref>); this finding was confirmed using qPCR to measure <italic>Ccr1</italic> mRNA (<xref ref-type="fig" rid="fig6">Figure 6H</xref>).</p><p>Our finding that CCR1 is expressed primarily in Müller cells suggests that this receptor may play a key functional role in these cells. We therefore measured whether three genes encoding markers of activated Müller cells—namely, <italic>Ccl2</italic>, <italic>Cxcl1</italic>, and/or <italic>Cxcl10</italic>—are upregulated following photic injury. Consistent with the previous reports (<xref ref-type="bibr" rid="bib73">Natoli et al., 2017</xref>; <xref ref-type="bibr" rid="bib86">Rutar et al., 2015</xref>), we found increased expression of all three genes following photic injury (<xref ref-type="fig" rid="fig6">Figure 6I–K</xref>). In addition, treating mice with the CCR1 inhibitor BX471 reduced expression to control levels (<xref ref-type="fig" rid="fig6">Figure 6I–K</xref>). Taken together, these results indicate that inhibiting CCR1 can reduce the retinal inflammation induced by photic injury and increase the survival of photoreceptor cells.</p></sec><sec id="s2-7"><title>Inhibiting CCR1 reduces the neurotoxic effects of M2a macrophages</title><p>Given that CCR1 is a chemokine receptor expressed by a wide range of immune cells, including mononuclear cells (<xref ref-type="bibr" rid="bib32">Gao et al., 1993</xref>; <xref ref-type="bibr" rid="bib57">Mantovani et al., 2006</xref>), we asked whether inhibiting this receptor can affect the functional properties of M2a hMdɸs via an autocrine signaling process. We found that both M1 and M2a hMdɸs express CCR1 (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>); however, cell sorting analysis revealed that a significantly larger percentage of M2a hMdɸs express CCR1 compared to M1 hMdɸs (<xref ref-type="fig" rid="fig7">Figure 7D</xref>), suggesting that M2a hMdɸs may be more susceptible to the effects of inhibiting CCR1. We therefore examined whether inhibiting CCR1 could reduce M2a hMdɸ-mediated neurotoxicity and found that treating M2a hMdɸs with either 0.5 µM or 5 µM BX471 significantly reduced their production of ROS (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). In addition, treating monocytes from patients with AMD with 10 µM BX471 significantly reduced the ability of M2a to attract monocytes (<xref ref-type="fig" rid="fig7">Figure 7F</xref>), indicating that the recruitment of mononuclear cells by M2a hMdɸs is mediated in part by CCR1 signaling.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Inhibiting CCR1 modulates the functional properties of M2a hMdɸs.</title><p>(<bold>A–C</bold>) M1 (<bold>A</bold>) and M2a (<bold>B</bold>) hMdɸs were immunostained for CCR1 (green); magnified views are shown below. (<bold>D</bold>) Summary of the percentage of CCR1-postive cells measured using cell sorting analysis of CCR1-stained M1 hMdɸ and M2a hMdɸs (n=5 per group, Student’s t-test). (<bold>E</bold>) Summary of reactive oxygen species (ROS) levels measured in untreated M2a hMdɸs and M2a hMdɸs treated with 0.5 or 5 µM BX471 (n=4 per group, one-way ANOVA with multiple comparisons). (<bold>F</bold>) Summary of the migration of monocytes treated or not with 10 µM BX471 that migrated toward the M2a hMdɸs using a Boyden chamber (n=3 per group, one-way ANOVA with multiple comparisons). Data shown as mean ± SEM. p-Values indicated by *p&lt;0.05 and **p&lt;0.01. Scale bars: 50 µm (<bold>A–C</bold>) and 20 µm (insets in A–C).</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Cell sorting analysis of CCR1-stained M1 hMdɸ and M2a hMdɸs.</title><p>Reactive oxygen species (ROS) levels and migration level measured in M2a hMdɸs groups.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81208-fig7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81208-fig7-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The role of monocytes—and macrophages in particular—in the pathogenesis of AMD has received increasing attention in recent years. Here, we provide additional insights into the function of specific hMdɸ phenotypes in the context of aAMD. We found that M2a hMdɸs mediate neurotoxicity in both in vitro and in vivo models of aAMD. In addition, and contrary to the prevailing hypothesis that M1 macrophages likely underlie tissue damage during inflammation, we found that M1 macrophages do not appear to play a major role in retinal damage in the context of aAMD. With respect to the potential underlying mechanism, we found that M2a hMdɸs produce high levels of ROS ex vivo; however, the in vivo effects of M2a hMdɸs may also be mediated by additional mechanisms such as increased production of cytokines that promote neurotoxicity and drive the recruitment of additional mononuclear cells. These findings may therefore explain the relatively high contribution of M2a macrophages to the pathogenesis of AMD. Indeed, oxidative stress—particularly ROS-induced cellular damage—was recently reported as a cause of retinal inflammation (<xref ref-type="bibr" rid="bib2">Abokyi et al., 2020</xref>), and the recruitment of other immune cell types can exacerbate inflammation in the eye, an immune-privileged organ in which overstimulation of the immune system can be detrimental (<xref ref-type="bibr" rid="bib14">Buschini et al., 2011</xref>).</p><p>By examining the molecular mechanism by which M2a hMdɸs drive retinal damage, we found that these cells can interact with retinal cells via the chemokine receptor CCR1 to mediate photoreceptor cell death. Although this receptor is expressed by a wide range of immune cell types and plays a key role in recruiting monocytes (<xref ref-type="bibr" rid="bib103">Trebst et al., 2002</xref>), our results provide the first evidence that CCR1 is also expressed in Müller cells<italic>,</italic> and this expression increases during acute retinal damage (e.g., following photic injury) and during progressive retinal degeneration (e.g., in the rd10 mouse). We also found increased retinal expression of CCR1 in senescent mice, supporting the notion that this receptor is involved in age-related neurodegenerative diseases, including AMD. Finally, we found that inhibiting CCR1 significantly reduced the severity of retinal damage induced by photic injury, suggesting that CCR1 antagonists may have therapeutic applications in aAMD. Further experiments are required to assess the effect of CCR1 inhibition in rd10 and senescent mice and validate the protective effect of CCR1 antagonist during retinal degeneration. Nevertheless, recent studies performed on human AMD materials revealing an increased expression/secretion of CCR1 and its ligands (<xref ref-type="bibr" rid="bib44">Joo et al., 2021</xref>; <xref ref-type="bibr" rid="bib87">Saddala et al., 2019</xref>), supporting the notion that CCR1 could represent a potential therapeutic target for treating AMD disease.</p><p>Our data support the notion that infiltrating monocytes interact with Müller cells during retinal disease, with deleterious effects. Although largely known for their structural role in the retina, Müller cells also play an essential role in maintaining metabolic homeostasis and function in the retina. For example, Müller cells can exchange ions, water, and bicarbonate molecules in order to regulate the composition of the extracellular fluid, and these cells use a variety of complex mechanisms to regulate synaptic activity, guide incoming light, and both support and protect neurons (<xref ref-type="bibr" rid="bib82">Reichenbach and Bringmann, 2013</xref>). Importantly, Müller cells also serve as a source of cytokines and growth factors that drive neuronal and immune responses (<xref ref-type="bibr" rid="bib1">Abcouwer, 2017</xref>; <xref ref-type="bibr" rid="bib22">Coughlin et al., 2017</xref>). During ocular inflammation, Müller cells are activated by a process known as gliosis, which allows them to interact with immune cells and microglial cells recruited to the site of inflammation (<xref ref-type="bibr" rid="bib11">Bringmann et al., 2006</xref>). With respect to their role in pathogenesis, previous studies suggest that Müller cells are associated with the progression of several inflammatory eye diseases such as diabetic retinopathy (<xref ref-type="bibr" rid="bib16">Capozzi et al., 2018</xref>) by activating the CD40 receptor (<xref ref-type="bibr" rid="bib78">Portillo et al., 2014</xref>; <xref ref-type="bibr" rid="bib79">Portillo et al., 2016</xref>; <xref ref-type="bibr" rid="bib80">Portillo et al., 2017</xref>) or by acting upon the microvascular to promote angiogenesis (<xref ref-type="bibr" rid="bib101">Sugiyama et al., 2004</xref>; <xref ref-type="bibr" rid="bib113">Xin et al., 2013</xref>).</p><p>Müller cells have also been shown to promote the development of glaucoma in an experimental model of chronic ocular hypertension (<xref ref-type="bibr" rid="bib123">Zhong-feng and Xiong-li, 2016</xref>). In addition, other studies suggest that these cells play a role in the development of proliferative vitreoretinopathy (<xref ref-type="bibr" rid="bib12">Bringmann and Wiedemann, 2012</xref>), retinitis pigmentosa, and AMD (<xref ref-type="bibr" rid="bib61">Massengill et al., 2018</xref>). Indeed, drusen formation has been associated with Müller cells gliosis (<xref ref-type="bibr" rid="bib102">Telegina et al., 2018</xref>; <xref ref-type="bibr" rid="bib112">Wu et al., 2003</xref>). However, the mechanism by which Müller cells contribute to the progression of AMD has not been identified. Here, we show that CCR1 expression in Müller cells is correlated directly with retinal function in an animal model that recapitulates many of the features associated with aAMD. Furthermore, we show that inhibiting CCR1 reduces Müller cell activation and reduces both retinal inflammation and photoreceptor cell loss.</p><p>Despite having distinct etiologies, both retinitis pigmentosa and AMD culminate in the loss of photoreceptor cells. Using models for both diseases, we found that CCR1 expression in Müller cells is correlated with photoreceptor cell death. Although previous studies have shown that Müller cells can directly cause the death of retinal ganglion cells (<xref ref-type="bibr" rid="bib115">Xue et al., 2016</xref>) and endothelial cells (<xref ref-type="bibr" rid="bib79">Portillo et al., 2016</xref>), the notion that Müller cells can be activated by neurotoxic macrophages—and thus may directly cause the death of photoreceptor cells—is novel and warrants further study.</p><p>Müller cells were shown previously to induce photoreceptor cell death by recruiting immune cells (<xref ref-type="bibr" rid="bib62">Matsumoto et al., 2018</xref>) and through crosstalk with microglial cells (<xref ref-type="bibr" rid="bib107">Wang et al., 2011</xref>). Similarly, we found that inhibiting CCR1 reduced macrophage infiltration and prevented activation of microglial cells. Interestingly, previous studies found that the chemokine receptor ligand CCL2 can act as an inflammatory cytokine, promoting photoreceptor cell death by recruiting macrophages (<xref ref-type="bibr" rid="bib70">Nakazawa et al., 2007</xref>), while other studies found that the ligand CXCL10 can activate microglial cells via the CCR3 receptor (<xref ref-type="bibr" rid="bib19">Clarner et al., 2015</xref>). Here, we found that inhibiting CCR1 was associated with decreased expression of CCL2 and—albeit to a slightly lesser extent—CXCL10 in Müller cells. Taken together, these findings suggest that CCR1 may play an essential role in the activation of Müller cells, thus leading to photoreceptor cell death.</p><p>CCR1 was first identified as a chemokine receptor expressed in specific immune cell types such as monocytes (<xref ref-type="bibr" rid="bib105">Tsou et al., 1998</xref>), which are recruited during photic injury (<xref ref-type="bibr" rid="bib86">Rutar et al., 2015</xref>). Although our results provide the first evidence that CCR1 is expressed in Müller cells, we cannot exclude the possibility that the systemically injected CCR1 inhibitor BX471 may have prevented the infiltration of immune cells in the retina, thereby reducing retinal inflammation and protecting photoreceptor cells from apoptosis. In addition, we found that BX471 significantly decreased the number of macrophages recruited to the photic-injured retina in vivo and reduced the capacity of M2a hMdɸs to attract human monocytes in vitro. Moreover, we found that inhibiting CCR1 altered the functional properties of M2a hMdɸs, rendering them less neurotoxic by reducing their production of ROS.</p><p>Reducing the recruitment of monocytes by inhibiting chemokine receptors has been explored as a possible therapeutic strategy for treating several inflammatory diseases (<xref ref-type="bibr" rid="bib93">Sennlaub et al., 2013</xref>). With respect to ocular inflammatory disease, a recent clinical trial tested a dual CCR2/CCR5 antagonist for treating diabetic macular edema; however, the results of the phase 2 clinical trial showed that this treatment was inferior to currently approved treatments (<xref ref-type="bibr" rid="bib31">Gale et al., 2018</xref>). This is consistent with the suggested role of Müller cells in photoreceptor cell death. Although we found that both CCR2 and CCR5 were upregulated in the photic injury model and in rd10 mice, these receptors do not appear to be expressed in Müller cells. Finally, although CCR1 antagonists have been tested in clinical trials for the treatment of endometriosis and leukemia, their therapeutic value with respect to ocular diseases has not been investigated.</p><p>In summary, our results indicate that the mechanism underlying CCR1-mediated photoreceptor cell death seems to include an intrinsic retinal process involving the activation of Müller cells, as well as the recruitment of neurotoxic macrophages to the retina and the functional modulation of M2a hMdɸs. These complementary roles played by CCR1—which include gliosis and the recruitment and polarization of macrophages in the retina—suggest that this receptor may serve as a promising new target for treating ocular degenerative diseases such as aAMD.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Patients</title><p>A total of 33 patients with AMD (14 women and 19 men) 77.1±3 years of age (range: 63–95 years) were recruited at the Retina Clinic in the Department of Ophthalmology at the Hadassah-Hebrew University Medical Center in Jerusalem, Israel. The criteria for establishing a diagnosis of AMD included &gt;55 years of age and clinical findings of intermediate or advanced AMD in accordance with the 1999 AREDS (Age-Related Eye Disease Study) criteria (<xref ref-type="bibr" rid="bib3">Age-Related Eye Disease Study Research, 1999</xref>). Moreover, we excluded eyes with high myopia (&gt;6 diopters), trauma, other retinal disease, and/or uveitis. We also excluded patients who presented with a major systemic illness such as cancer, autoimmune disease, congestive heart failure, and/or uncontrolled diabetes. All participating patients provided written informed consent, and the study was approved by our institutional ethics committee.</p></sec><sec id="s4-2"><title>Preparation of monocytes and macrophages</title><p>Whole blood samples (30 ml) were collected from patients with AMD in EDTA tubes (BD Biosciences, Franklin Lakes, NJ, USA). Monocytes were then isolated from these whole blood samples using negative selection as described previously (<xref ref-type="bibr" rid="bib37">Grunin et al., 2012</xref>). In brief, PBMCs were separated from the whole blood using a Histopaque-Ficoll gradient (Sigma-Aldrich, Munich, Germany) and washed twice by centrifugation at 1500 rpm for 10 min to remove the platelets; live cells were counted using a hemocytometer with the trypan blue exclusion method. Total blood monocytes, including CD14<sup>++</sup>CD16<sup>-</sup> and CD14<sup>+</sup>CD16<sup>+</sup> monocytes, were then isolated using the EasySep negative selection kit (Stemcell Technologies, Vancouver, Canada) in accordance with the manufacturer’s instructions.</p><p>To prepare macrophages, PBMCs were isolated from the whole blood samples as described above, stimulated with M-CSF (macrophage colony-stimulating factor; PeproTech, Rocky Hill, NJ, USA) to produce non-activated (M0) macrophages, and then activated with either IFN-γ and LPS (to produce M1 hMdɸs), IL-4 and IL-13 (to produce M2a hMdɸs), or IL-10 (to produce M2c macrophages) as previously described (<xref ref-type="bibr" rid="bib9">Bouhlel et al., 2007</xref>; <xref ref-type="bibr" rid="bib34">Gelinas et al., 2011</xref>; <xref ref-type="bibr" rid="bib55">Mantovani et al., 2002</xref>; <xref ref-type="bibr" rid="bib59">Martinez, 2009</xref>; <xref ref-type="bibr" rid="bib76">Pelegrin and Surprenant, 2009</xref>). In brief, PBMCs were suspended in RPMI 1640 medium (Biological Industries, Kibbutz Beit-Haemek, Israel) and seeded at 3×10<sup>7</sup> cells/cm<sup>2</sup> in six-well plates. The monocytes were then incubated at 37°C in 5% CO<sub>2</sub> for 2 hr, washed with PBS, and then cultured for 7 days in RPMI 1640 supplemented with 10% (vol/vol) fetal calf serum (FCS), 1% non-essential amino acids, 2 mmol/L L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, 100 µg/ml streptomycin, and 50 ng/ml M-CSF; M-CSF was included in the growth medium to drive maturation of the monocytes into macrophages. M1 hMdɸs were obtained by the addition of 20 ng/ml IFN-γ (PeproTech) and 100 ng/ml LPS (Sigma-Aldrich) on day 6, M2a hMdɸs were obtained by the addition of 50 ng/ml IL-13 (PeproTech) and 20 ng/ml IL-4 (PeproTech) on day 5, and M2c hMdɸs were obtained by the addition of 50 ng/ml IL-10 (PeproTech) on day 5. hMdɸ cells that were not activated were classified as unpolarized HMdɸs (M0). M1 macrophages require 24 hr for polarization, whereas M2a and M2c cells require 48 hr (<xref ref-type="bibr" rid="bib4">Allavena et al., 1998</xref>); therefore, the hMdɸs were polarized on different days so that the in vitro and in vivo experiments could be performed on the same day.</p></sec><sec id="s4-3"><title>Macrophage co-cultures with mouse retinal explants</title><p>The various groups of polarized hMdɸs were harvested and seeded for a minimum of 2 hr on a polycarbonate filter in serum-free DMEM (Biological Industries) supplemented with glutamine and penicillin-streptomycin. In parallel, 6-week-old C57BL/6 mice (n=9) were anesthetized and euthanized via cervical dislocation. Both eyes (n=18) were then enucleated and placed in cold serum-free DMEM supplemented with glutamine and penicillin-streptomycin. The retinas were gently detached from the choroid tissue and immediately placed on the polycarbonate filter so that the hMdɸs were in contact with the photoreceptor layer. For retinal explants cultivated without direct contact with hMdɸs (n=18), 10<sup>5</sup> hMdɸs were seeded in the bottom well of a Boyden chamber, and the explant was placed in the upper chamber. After incubation for 18 hr, the mouse retinas were fixed in 4% paraformaldehyde (PFA) for 30 min at room temperature (RT) and then permeabilized for 30 min on ice in methanol, followed by 30 min on ice in a 2:1 mixture of methanol/acetone. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was then performed using an In Situ Cell Death Detection Kit, TMR red (La Roche, Basel, Switzerland) in accordance with the manufacturer’s instructions. For rhodopsin and RPE65 immunostaining, retinal explants were incubated with either mouse anti-rhodopsin (10 µg/ml; ab3267, Abcam, Cambridge, UK) or mouse anti-RPE65 (10 µg/ml; ab13826, Abcam) overnight at 4°C, washed, and then incubated with donkey anti-mouse IgG-Alexa Fluor 488 (1 µg/ml, ab150109, Abcam) for 1 hr at RT. A Zeiss LSM 710 confocal microscope was used to visualize the TUNEL-stained cells in 11 randomly selected retinal fields.</p></sec><sec id="s4-4"><title>Reverse transcription and real-time qPCR</title><p>RNA was extracted from isolated hMdɸs and retina samples using TRIzol Reagent (Sigma-Aldrich) in accordance with the manufacturer’s instructions. The RNA quality and quantity were measured using a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA, USA) and a bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), and RNA was reverse-transcribed to create cDNA using the qScript cDNA Synthesis Kit (Quantabio, Beverly, MA, USA) in accordance with the manufacturer’s instructions. qPCR was then performed using the PerfeCTa SYBR Green FastMix kit (Quantabio); the gene-specific primers (Sigma-Aldrich) used in this study are listed in <xref ref-type="table" rid="table1">Table 1</xref>. Each gene was amplified in triplicate, and the expression level of each gene was normalized to human <italic>GAPDH</italic> or mouse <italic>Gapdh</italic> as an endogenous control using the standard 2(ΔΔCT) method (<xref ref-type="bibr" rid="bib53">Livak and Schmittgen, 2001</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>qPCR Primer Sequences.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Gene</th><th align="left" valign="bottom">Forward (5’–3’)</th><th align="left" valign="bottom">Reverse (5’–3’)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Human <italic>GAPDH</italic><break/>Human CXCL10<break/>Human CCL17<break/>Human CD163</td><td align="left" valign="bottom"><named-content content-type="sequence">AACAGCCTCAAGATCATCAGC</named-content><break/><named-content content-type="sequence">GGTGAGAAGAGATGTCTGAATCC</named-content><break/><named-content content-type="sequence">AGGGATGCCATCGTTTTTGTAA</named-content><break/><named-content content-type="sequence">CAGTGCAGAAAACCCCACAA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GGATGATGTTCTGGAGAGCC</named-content><break/><named-content content-type="sequence">GTCCATCCTTGGAAGCACTGCA</named-content><break/><named-content content-type="sequence">GCTTCAAGACCTCTCAAGGCT</named-content><break/><named-content content-type="sequence">AAAGGATGACTGACGGGATGA</named-content></td></tr><tr><td align="left" valign="bottom">Human <italic>CCL13</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">ATCTCCTTGCAGAGGCTGAA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CTTCTCCTTTGGGTCAGCAC</named-content></td></tr><tr><td align="left" valign="bottom">Human <italic>CCL23</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TTTGAAACGAACAGCGAGTG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CAGCATTCTCACGCAAACC</named-content></td></tr><tr><td align="left" valign="bottom">Human <italic>CCL14</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">ATACAGCTAAAGTTGGTGGGGG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TGGTGATGAAGACAATTCCGGG</named-content></td></tr><tr><td align="left" valign="bottom">Human <italic>CCR1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">AAGTCCCTTGGAACCAGAGAGAAG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CCAACCAGGCCAATGACAAA</named-content></td></tr><tr><td align="left" valign="bottom">Mouse <italic>Gapdh</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">AACTTTGGCATTGTGGAAGG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">ACACATTGGGGGTAGGAACA</named-content></td></tr><tr><td align="left" valign="bottom">Mouse <italic>Ccr1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GTTGGGACCTTGAACCTTGA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CCCAAAGGCTCTTACAGCAG</named-content></td></tr><tr><td align="left" valign="bottom">Mouse <italic>Ccr2</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GAAGAGGGCATTGGATTCAC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TATGCCGTGGATGAACTGAG</named-content></td></tr><tr><td align="left" valign="bottom">Mouse <italic>Ccr5</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">TCTCCTAGCCAGAGGAGGTG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TGTCATAGCTATAGGTCGGAACTG</named-content></td></tr><tr><td align="left" valign="bottom">Mouse <italic>Adgre1</italic><xref ref-type="table-fn" rid="table1fn1">*</xref></td><td align="left" valign="bottom"><named-content content-type="sequence">GCATCATGGCATACCTGTTC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AGTCTGGGAATGGGAGCTAA</named-content></td></tr><tr><td align="left" valign="bottom">Mouse <italic>Ccl2</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">AGGTCCCTGTCATGCTTCTG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TCTGGACCCATTCCTTCTTG</named-content></td></tr><tr><td align="left" valign="bottom">Mouse <italic>Cxcl1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GACCATGGCTGGGATTCACC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CCAAGGGAGCTTCAGGGTCA</named-content></td></tr><tr><td align="left" valign="bottom">Mouse <italic>Cxcl10</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CATCCCTGCGAGCCTATCC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CATCTCTGCTCATCATTCTTTTTCA</named-content></td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p>Encodes the F4/80 protein, also known as EMR1 (EGF-like module-containing mucin-like hormone receptor-like 1).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4-5"><title>Photo-oxidative retinal injury and intravitreal injections</title><p>Albino BALB/c mice that were homozygous for the wild-type <italic>Crb1</italic>, <italic>Gnat2</italic>, and <italic>Rpe65</italic> genes were used for this study (<xref ref-type="bibr" rid="bib18">Chang et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Mattapallil et al., 2012</xref>; <xref ref-type="bibr" rid="bib109">Wenzel et al., 2003</xref>). Photic injury was induced essentially as described previously (<xref ref-type="bibr" rid="bib36">Grimm and Remé, 2013</xref>), with optimization to ensure an approximately 50% reduction in ONL thickness as previously described (<xref ref-type="bibr" rid="bib27">Elbaz-Hayoun et al., 2019</xref>). In brief, after 1 hr of dark adaptation, 6-week-old BALB/c mice raised under a standard light/dark cycle were exposed to 8000 lux of white light for 3 hr. Photic injury was then induced as follows, according to the appropriate circadian rhythm: the pupils were dilated with Cyclogyl (one drop per eye, Sandoz Farmaceutica S.A., Madrid, Spain) and 5% phenylephrine (Fischer Pharmaceutical Labs, Tel Aviv, Israel) at 9:30 am under a red light; the light level was adjusted at 9:45 am, and photic injury was induced for 3 hr (from 10:00 am to 1:00 pm), during which the mice were placed in a cage (maximum two mice per cage) lined with aluminum foil, and the temperature was maintained below 30°C.</p><p>Immediately after photic injury, the mice received an intravitreal injection of either human monocytes or hMdɸs that were labeled with the Vybrant DiO tracer (Invitrogen-Molecular Probes, Carlsbad, CA, USA), and then returned to the standard light/dark cycle. For these experiments, we chose the intravitreal route over the subretinal route in order to avoid triggering an immune response due to RPE immunogenicity and the potentially higher risk of RPE and/or Bruch’s membrane breakthrough (<xref ref-type="bibr" rid="bib110">Westenskow et al., 2015</xref>); moreover, intravitreal injection allows the injected cells to distribute across the entire retina, creating a wider and less-biased effect on ONL thickness. To compare the effect of monocytes from AMD patients with those from unaffected aged-matched control, 10<sup>5</sup> human monocytes extracted from AMD patients were injected into the right eye, while the left eye received an injection of monocyte from an unaffected individual.</p><p>To assess monocyte or hMdɸs from AMD patients, for each mouse, 10<sup>5</sup> human monocytes or hMdɸs suspended in PBS were injected into the right eye, while the left eye received an injection of PBS as a control. As an additional control, some mice were not exposed to light and did not receive an intravitreal injection of monocytes or hMdɸs. An antibiotic ointment (5% chloramphenicol) was applied after each intravitreal injection.</p></sec><sec id="s4-6"><title>CCR1 blocking treatment</title><p>Immediately after photic injury was induced, the mice received subcutaneous injections of either the CCR1-specific antagonist BX471 (50 mg/kg body weight; Tocris, Bristol, UK) or vehicle (40% cyclodextrin in saline) every 12 hr for 5 days. For injection, BX471 was dissolved at a final concentration of 10 mg/ml in saline containing 40% (wt/vol) cyclodextrin (Sigma-Aldrich); the solution was mixed thoroughly and dissolved overnight at 4°C, after which the pH was adjusted to 4.5 with NaOH, and the solution was filtered through a 0.45 µm filter.</p></sec><sec id="s4-7"><title>Electroretinography recording and in vivo retinal imaging</title><p>Seven days after photic injury, the pupils were dilated with tropicamide (Fischer Pharmaceutical Labs) and phenylephrine (Fischer Pharmaceutical Labs), and the corneas were kept moist by application of carboxymethylcellulose (Fischer Pharmaceutical Labs). Retinal images were obtained using a Spectralis Optical Coherence Tomography device and a Micron III retinal microscope (Phoenix Research Labs, San Francisco, CA, USA). Blue autofluorescence images were obtained using an excitation wavelength of 488 nm, and full-field ERG was performed in dark-adapted mice. During ERG recording, the eyes were anesthetized with oxybuprocaine hydrochloride drops (Fischer Pharmaceutical Labs). All procedures were performed in dim red lighting or in total darkness, and the mice were kept warm throughout the recording. During the recording, the mouse was positioned facing the center of a Ganzfeld bowl, ensuring equal, simultaneous illumination of both eyes. ERG data were recorded inside a Faraday cage using an Espion computerized system (Diagnosys LLC, Littleton, MA, USA). Dark-adapted ERG responses to a series of white flashes at increasing intensity (from 0.000006 to 9.6 cd·s/m<sup>2</sup>) were recorded at inter-stimulus intervals increasing from 10 s (for the lowest-intensity flashes) to 90 s (for the highest-intensity flashes). Light adaptation was performed using a background illumination of 30 cd/m<sup>2</sup>. For analysis, the b-wave amplitude was measured from the trough of the a-wave to the peak of the b-wave.</p></sec><sec id="s4-8"><title>Immunohistochemistry</title><p>Seven days after photic injury, the mice were euthanized, the eyes were enucleated and sectioned at 10 µm using a cryostat, and the sections were immunostained as previously described (<xref ref-type="bibr" rid="bib39">Hagbi-Levi et al., 2017</xref>). In brief, the eyes were fixed in 4% PFA for 2 hr and then placed in 30% sucrose overnight at 4°C. The eyes were then placed in optimal cutting temperature compound (Scigen Scientific, Gardena CA, USA), and 10 µm sections were cut and placed in blocking solution (PBS containing 10% serum and 0.1% Triton X-100) for 1 hr at RT. The sections were then incubated in primary antibody overnight at 4°C; the following day, the sections were incubated in secondary antibody for 1 hr at RT. The nuclei were counterstained with DAPI, and the sections were visualized using a fluorescence microscope. For hMdɸ labeling, after polarization the cells were washed once with PBS and then fixed with 4% PFA for 30 min at RT; after three washes with PBS, the cells were incubated in blocking solution and immunostained with primary and secondary antibodies as described above.</p><p>The following primary antibodies were used for these experiments: rabbit anti-4 HNE antibody (10 µg/ml; ab46545, Abcam), rat anti-cd11b antibody (0.5 µg/ml; ab64347, Abcam), mouse anti-human CCR1 (25 µg/ml; mab145, R&amp;D Systems, Minneapolis, MN, USA), rat anti-mouse CCR1 (25 µg/ml; mab5986, R&amp;D Systems), rat anti-mouse-CCR5 (10 µg/ml; ab11466, Abcam), rabbit anti-mouse CCR2 (5 µg/ml; NBP2-67700, Novus Biologicals, Littleton, CO, USA), rabbit anti-mouse GFAP (0.5 µg/ml; ab64347, Abcam), and rabbit anti-mouse Iba1 (5 µg/ml; ab153696, Abcam). The following secondary antibodies were used: donkey anti-mouse IgG-Alexa Fluor 488 (ab150109; Abcam), donkey anti-rat IgG-Alexa Fluor 555 (ab150154; Abcam), and goat anti-rabbit IgG-Alexa Fluor 488 (ab150085; Abcam). TUNEL staining was performed using the In Situ Cell Death Detection Kit, TMR red (La Roche, Basel, Switzerland) in accordance with the manufacturer’s instructions.</p><p>To measure the thickness of the ONL, the sections were stained with DAPI and the number of photoreceptor nuclei was counted at fixed distances from the ONH.</p></sec><sec id="s4-9"><title>Measurement of ROS</title><p>Human hMdɸs were cultured in six-well plates for 6 days and polarized as described above. To block CCR1, 0.5 µM or 5 µM BX471 was added to M2a hMdɸ cultures for 1 hr at 37°C. ROS production was measured using the DCFDA Cellular ROS Detection Assay (ab113851; Abcam) and a fluorescence microplate reader (Tecan Group, Männedorf, Switzerland) in accordance with the manufacturer’s instructions.</p></sec><sec id="s4-10"><title>Multiplex ELISA</title><p>After the macrophages were polarized (see above), the culture medium was collected and stored at −80°C. A panel of 120 cytokines was then measured in the culture medium using the Human Cytokine Array GS2000 (RayBiotech Life, Inc, Norcross, GA, USA) in accordance with the manufacturer’s instructions (<xref ref-type="table" rid="table2">Table 2</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Multiplex ELISA results.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">p-Value</th><th align="left" valign="bottom">M1:M2a ratio</th><th align="left" valign="bottom">M2a</th><th align="left" valign="bottom">M1</th><th align="left" valign="bottom">Protein name</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">0.0123</td><td align="left" valign="bottom">0.00</td><td align="left" valign="bottom">373</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">TGFa</td></tr><tr><td align="char" char="." valign="bottom">0.0009</td><td align="left" valign="bottom">0.10</td><td align="left" valign="bottom">7457</td><td align="left" valign="bottom">826</td><td align="left" valign="bottom">CCL14</td></tr><tr><td align="char" char="." valign="bottom">0.0001</td><td align="left" valign="bottom">0.11</td><td align="left" valign="bottom">36,571</td><td align="left" valign="bottom">3821</td><td align="left" valign="bottom">CCL13</td></tr><tr><td align="char" char="." valign="bottom">0.0020</td><td align="left" valign="bottom">0.27</td><td align="left" valign="bottom">14,645</td><td align="left" valign="bottom">3866</td><td align="left" valign="bottom">CCL17</td></tr><tr><td align="char" char="." valign="bottom">0.0097</td><td align="left" valign="bottom">0.51</td><td align="left" valign="bottom">6530</td><td align="left" valign="bottom">3007</td><td align="left" valign="bottom">CCL23</td></tr><tr><td align="char" char="." valign="bottom">0.0159</td><td align="left" valign="bottom">0.52</td><td align="left" valign="bottom">82,038</td><td align="left" valign="bottom">43,946</td><td align="left" valign="bottom">CCL24</td></tr><tr><td align="char" char="." valign="bottom">0.0409</td><td align="left" valign="bottom">0.70</td><td align="left" valign="bottom">74,990</td><td align="left" valign="bottom">48,575</td><td align="left" valign="bottom">PDGFB</td></tr><tr><td align="char" char="." valign="bottom">0.0298</td><td align="left" valign="bottom">0.78</td><td align="left" valign="bottom">937</td><td align="left" valign="bottom">712</td><td align="left" valign="bottom">IL-7</td></tr><tr><td align="char" char="." valign="bottom">0.0287</td><td align="left" valign="bottom">0.81</td><td align="left" valign="bottom">869</td><td align="left" valign="bottom">688</td><td align="left" valign="bottom">TNFb</td></tr><tr><td align="char" char="." valign="bottom">0.0026</td><td align="left" valign="bottom">99.24</td><td align="left" valign="bottom">1458</td><td align="left" valign="bottom">109,591</td><td align="left" valign="bottom">CXCL13</td></tr><tr><td align="char" char="." valign="bottom">0.0558</td><td align="left" valign="bottom">40.72</td><td align="left" valign="bottom">394</td><td align="left" valign="bottom">9887</td><td align="left" valign="bottom">CSF3</td></tr><tr><td align="char" char="." valign="bottom">0.00002</td><td align="left" valign="bottom">39.66</td><td align="left" valign="bottom">16,545</td><td align="left" valign="bottom">238,286</td><td align="left" valign="bottom">IL-6</td></tr><tr><td align="char" char="." valign="bottom">0.0002</td><td align="left" valign="bottom">17.91</td><td align="left" valign="bottom">635</td><td align="left" valign="bottom">7254</td><td align="left" valign="bottom">CXCL11</td></tr><tr><td align="char" char="." valign="bottom">0.0002</td><td align="left" valign="bottom">15.27</td><td align="left" valign="bottom">2979</td><td align="left" valign="bottom">32,877</td><td align="left" valign="bottom">CCL19</td></tr><tr><td align="char" char="." valign="bottom">0.0008</td><td align="left" valign="bottom">6.33</td><td align="left" valign="bottom">5322</td><td align="left" valign="bottom">30,523</td><td align="left" valign="bottom">CCL20</td></tr><tr><td align="char" char="." valign="bottom">0.0032</td><td align="left" valign="bottom">5.47</td><td align="left" valign="bottom">28,468</td><td align="left" valign="bottom">94,382</td><td align="left" valign="bottom">CCL5</td></tr><tr><td align="char" char="." valign="bottom">0.0108</td><td align="left" valign="bottom">4.74</td><td align="left" valign="bottom">952</td><td align="left" valign="bottom">4515</td><td align="left" valign="bottom">VEGF</td></tr><tr><td align="char" char="." valign="bottom">0.0210</td><td align="left" valign="bottom">3.08</td><td align="left" valign="bottom">5085</td><td align="left" valign="bottom">14,169</td><td align="left" valign="bottom">IL-10</td></tr><tr><td align="char" char="." valign="bottom">0.0572</td><td align="left" valign="bottom">2.60</td><td align="left" valign="bottom">6683</td><td align="left" valign="bottom">18,212</td><td align="left" valign="bottom">CXCL6</td></tr><tr><td align="char" char="." valign="bottom">0.0219</td><td align="left" valign="bottom">2.50</td><td align="left" valign="bottom">14,774</td><td align="left" valign="bottom">27,516</td><td align="left" valign="bottom">CCL1</td></tr><tr><td align="char" char="." valign="bottom">0.0029</td><td align="left" valign="bottom">2.43</td><td align="left" valign="bottom">150</td><td align="left" valign="bottom">296</td><td align="left" valign="bottom">CXCL12</td></tr><tr><td align="char" char="." valign="bottom">0.0008</td><td align="left" valign="bottom">2.27</td><td align="left" valign="bottom">8696</td><td align="left" valign="bottom">19,269</td><td align="left" valign="bottom">CXCL10</td></tr><tr><td align="char" char="." valign="bottom">0.0019</td><td align="left" valign="bottom">1.40</td><td align="left" valign="bottom">31,868</td><td align="left" valign="bottom">44,135</td><td align="left" valign="bottom">CCL7</td></tr><tr><td align="char" char="." valign="bottom">0.0506</td><td align="left" valign="bottom">1.21</td><td align="left" valign="bottom">365</td><td align="left" valign="bottom">442</td><td align="left" valign="bottom">IL-11</td></tr></tbody></table></table-wrap></sec><sec id="s4-11"><title>In vitro migration assay</title><p>CD14<sup>++</sup>CD16<sup>-</sup> and CD14<sup>+</sup>CD16<sup>+</sup> monocytes were isolated as described above, and their migration was measured using a 24-well Boyden chamber assay (Corning, 5 µm pore size). In brief, conditioned medium obtained from 10<sup>5</sup> M1 hMdɸs or 10<sup>5</sup> M2a hMdɸs was harvested, centrifuged to remove cell debris, and placed in the bottom chamber of the plate. Next, 1.2×10<sup>5</sup> previously isolated monocytes suspended in 100 µl RPMI with 1% FCS were placed in the upper chamber.</p><p>To determine the effect of blocking CCR1 on monocyte migration, 10<sup>5</sup> M2a hMdɸs were first grown in the bottom chamber for 48 hr. The day of the experiment, fresh RPMI containing 1% FCS was used to fill the bottom chamber, and 1.2×10<sup>5</sup> previously isolated monocytes that were pretreated for 1 hr with either 10 µM BX471 or vehicle were placed in the upper chamber containing 100 µl RPMI with 1% FCS. After incubation for 2 hr at 37°C, the monocytes that migrated to the bottom chamber were measured using FACS analysis.</p></sec><sec id="s4-12"><title>Flow cytometry</title><p>To evaluate the effect of polarized hMdɸs on photoreceptor apoptosis in vitro, retinal explants that were either in contact with or not in contact with polarized hMdɸs were fixed, TUNEL stained as described above, and digested using a homogenizer in 500 ml PBS containing 100 mg/ml collagenase/dispase (10-269-638; La Roche). Samples (100 ml each) were then placed in tubes, washed twice with 2 ml FACS washing buffer containing 0.5% (wt/vol) BSA in PBS, and centrifuged at 1500 × <italic>g</italic> for 5 min to collect the cells. The cells were then filtered through a 60 µm mesh, and fluorescence intensity was immediately read using an LSR-II flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) in accordance with the manufacturer’s instructions.</p><p>To measure the level of CCR1 expression in M1 and M2a hMdɸs, the cells were fixed in 4% PFA for 20 min at RT and washed twice with PBS. The cells were then stained with mouse anti-human CCR1 antibody (2.5 µg/10<sup>6</sup> cells; mab145, R&amp;D Systems) for 20 min at RT, followed by donkey anti-mouse IgG-Alexa Fluor 488 antibody (1 µg/ml; ab150109, Abcam) for 20 min in the dark at RT. Each sample was then washed twice with PBS containing 0.5% (wt/vol) BSA and centrifuged at 1500 rpm for 5 min to collect the cells. The cells were then filtered through a 60 µm mesh, and fluorescence intensity was immediately read using an LSR-II flow cytometer (BD Biosciences) in accordance with the manufacturer’s instructions.</p></sec><sec id="s4-13"><title>Statistical analysis</title><p>The appropriate statistical tests were used based on the results of a test for normalcy and the sample distribution and parameters. The biostatistical software package InStat (GraphPad Software, San Diego, CA, USA) was used for data analysis. Data were analyzed using a one-way ANOVA followed by the Tukey-Kramer post hoc test or an unpaired Student’s t-test, where appropriate. Details of the number of replicates and the specific statistical test used are provided in the individual figure legends. Values over 2 standard deviations from the average were excluded from statistical analysis. The results are presented as the mean fold change ± the standard error of the mean (SEM).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Validation</p></fn><fn fn-type="con" id="con3"><p>Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Supervision</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Ethical approval for all experimental protocols and studies involving human subjects were provided by the Local Committee on Research Involving Human Subjects of the Hebrew University-Hadassah Medical School, the Helsinki Committee of Hadassah Medical Organization, and the Israel Ministry of Health's Helsinki Committee for Genetic Experiments on Human Subjects (File # 22-03.08.07). All patients and controls signed informed consent forms that adhered to the tenets of the Declaration of Helsinki before participating in the study.</p></fn><fn fn-type="other"><p>Ethical approval for all protocols involving animals was approved by the Authority for Biological and Biomedical Models (ABBM) and the University Ethics Committee for the Care and Use of Laboratory Animals at the Hebrew University, which is certified by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) (ethical approval number: MD-16-14796-3, NIH approval number: OPRR-A01-5011). All researchers working with laboratory animals received the approval of the ethics committee of the ABBM to ethically work with laboratory animals. All guidelines with regard to the humane and ethical treatment of laboratory animals (from ARVO) were followed to the utmost and all the methods used in this study were carried out in accordance with the approved guidelines for the study.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-81208-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Cytokines array result.</title></caption><media xlink:href="elife-81208-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abcouwer</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Müller cell-microglia cross talk drives neuroinflammation in diabetic retinopathy</article-title><source>Diabetes</source><volume>66</volume><fpage>261</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.2337/dbi16-0047</pub-id><pub-id pub-id-type="pmid">28108606</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abokyi</surname><given-names>S</given-names></name><name><surname>To</surname><given-names>CH</given-names></name><name><surname>Lam</surname><given-names>TT</given-names></name><name><surname>Tse</surname><given-names>DY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Central role of oxidative stress in age-related macular degeneration: Evidence from a review of the molecular mechanisms and animal models</article-title><source>Oxidative Medicine and Cellular Longevity</source><volume>2020</volume><elocation-id>7901270</elocation-id><pub-id pub-id-type="doi">10.1155/2020/7901270</pub-id><pub-id pub-id-type="pmid">32104539</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Age-Related Eye Disease Study Research</collab></person-group><year iso-8601-date="1999">1999</year><article-title>The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1</article-title><source>Controlled Clinical Trials</source><volume>20</volume><fpage>573</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1016/s0197-2456(99)00031-8</pub-id><pub-id pub-id-type="pmid">10588299</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Piemonti</surname><given-names>L</given-names></name><name><surname>Longoni</surname><given-names>D</given-names></name><name><surname>Bernasconi</surname><given-names>S</given-names></name><name><surname>Stoppacciaro</surname><given-names>A</given-names></name><name><surname>Ruco</surname><given-names>L</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages</article-title><source>European Journal of Immunology</source><volume>28</volume><fpage>359</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1521-4141(199801)28:01&lt;359::AID-IMMU359&gt;3.0.CO;2-4</pub-id><pub-id pub-id-type="pmid">9485215</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apte</surname><given-names>RS</given-names></name><name><surname>Richter</surname><given-names>J</given-names></name><name><surname>Herndon</surname><given-names>J</given-names></name><name><surname>Ferguson</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Macrophages inhibit neovascularization in a murine model of age-related macular degeneration</article-title><source>PLOS Medicine</source><volume>3</volume><elocation-id>e310</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0030310</pub-id><pub-id pub-id-type="pmid">16903779</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augustin</surname><given-names>AJ</given-names></name><name><surname>Kirchhof</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inflammation and the pathogenesis of age-related macular degeneration</article-title><source>Expert Opinion on Therapeutic Targets</source><volume>13</volume><fpage>641</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1517/14728220902942322</pub-id><pub-id pub-id-type="pmid">19456269</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baas</surname><given-names>DC</given-names></name><name><surname>Ho</surname><given-names>L</given-names></name><name><surname>Ennis</surname><given-names>S</given-names></name><name><surname>Merriam</surname><given-names>JE</given-names></name><name><surname>Tanck</surname><given-names>MWT</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>de Jong</surname><given-names>PTVM</given-names></name><name><surname>Cree</surname><given-names>AJ</given-names></name><name><surname>Griffiths</surname><given-names>HL</given-names></name><name><surname>Rivadeneira</surname><given-names>F</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>van Duijn</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>RT</given-names></name><name><surname>Barile</surname><given-names>GR</given-names></name><name><surname>Gorgels</surname><given-names>TGMF</given-names></name><name><surname>Vingerling</surname><given-names>JR</given-names></name><name><surname>Klaver</surname><given-names>CCW</given-names></name><name><surname>Lotery</surname><given-names>AJ</given-names></name><name><surname>Allikmets</surname><given-names>R</given-names></name><name><surname>Bergen</surname><given-names>AAB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The complement component 5 gene and age-related macular degeneration</article-title><source>Ophthalmology</source><volume>117</volume><fpage>500</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2009.08.032</pub-id><pub-id pub-id-type="pmid">20022638</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beatty</surname><given-names>S</given-names></name><name><surname>Koh</surname><given-names>HH</given-names></name><name><surname>Phil</surname><given-names>M</given-names></name><name><surname>Henson</surname><given-names>D</given-names></name><name><surname>Boulton</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The role of oxidative stress in the pathogenesis of age-related macular degeneration</article-title><source>Survey of Ophthalmology</source><volume>45</volume><fpage>115</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/s0039-6257(00)00140-5</pub-id><pub-id pub-id-type="pmid">11033038</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouhlel</surname><given-names>MA</given-names></name><name><surname>Derudas</surname><given-names>B</given-names></name><name><surname>Rigamonti</surname><given-names>E</given-names></name><name><surname>Dièvart</surname><given-names>R</given-names></name><name><surname>Brozek</surname><given-names>J</given-names></name><name><surname>Haulon</surname><given-names>S</given-names></name><name><surname>Zawadzki</surname><given-names>C</given-names></name><name><surname>Jude</surname><given-names>B</given-names></name><name><surname>Torpier</surname><given-names>G</given-names></name><name><surname>Marx</surname><given-names>N</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name><name><surname>Chinetti-Gbaguidi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties</article-title><source>Cell Metabolism</source><volume>6</volume><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2007.06.010</pub-id><pub-id pub-id-type="pmid">17681149</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowes Rickman</surname><given-names>C</given-names></name><name><surname>Farsiu</surname><given-names>S</given-names></name><name><surname>Toth</surname><given-names>CA</given-names></name><name><surname>Klingeborn</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>54</volume><fpage>RSF68</fpage><lpage>RSF80</lpage><pub-id pub-id-type="doi">10.1167/iovs.13-12757</pub-id><pub-id pub-id-type="pmid">24335072</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bringmann</surname><given-names>A</given-names></name><name><surname>Pannicke</surname><given-names>T</given-names></name><name><surname>Grosche</surname><given-names>J</given-names></name><name><surname>Francke</surname><given-names>M</given-names></name><name><surname>Wiedemann</surname><given-names>P</given-names></name><name><surname>Skatchkov</surname><given-names>SN</given-names></name><name><surname>Osborne</surname><given-names>NN</given-names></name><name><surname>Reichenbach</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Müller cells in the healthy and diseased retina</article-title><source>Progress in Retinal and Eye Research</source><volume>25</volume><fpage>397</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2006.05.003</pub-id><pub-id pub-id-type="pmid">16839797</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bringmann</surname><given-names>A</given-names></name><name><surname>Wiedemann</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Müller glial cells in retinal disease</article-title><source>Ophthalmologica. Journal International d’ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde</source><volume>227</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1159/000328979</pub-id><pub-id pub-id-type="pmid">21921569</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brüne</surname><given-names>B</given-names></name><name><surname>Weigert</surname><given-names>A</given-names></name><name><surname>Dehne</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Macrophage polarization in the tumor microenvironment</article-title><source>Redox Biology</source><volume>5</volume><elocation-id>419</elocation-id><pub-id pub-id-type="doi">10.1016/j.redox.2015.09.028</pub-id><pub-id pub-id-type="pmid">28162286</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buschini</surname><given-names>E</given-names></name><name><surname>Piras</surname><given-names>A</given-names></name><name><surname>Nuzzi</surname><given-names>R</given-names></name><name><surname>Vercelli</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Age related macular degeneration and drusen: neuroinflammation in the retina</article-title><source>Progress in Neurobiology</source><volume>95</volume><fpage>14</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2011.05.011</pub-id><pub-id pub-id-type="pmid">21740956</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Patel</surname><given-names>MM</given-names></name><name><surname>Tuo</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>TM</given-names></name><name><surname>Olsen</surname><given-names>TW</given-names></name><name><surname>Chan</surname><given-names>CCC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Macrophage polarization in the maculae of age-related macular degeneration: A pilot study</article-title><source>Pathology International</source><volume>61</volume><fpage>528</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1827.2011.02695.x</pub-id><pub-id pub-id-type="pmid">21884302</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capozzi</surname><given-names>ME</given-names></name><name><surname>Giblin</surname><given-names>MJ</given-names></name><name><surname>Penn</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Palmitic acid induces müller cell inflammation that is potentiated by co-treatment with glucose</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>5459</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-23601-1</pub-id><pub-id pub-id-type="pmid">29626212</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Hawes</surname><given-names>NL</given-names></name><name><surname>Hurd</surname><given-names>RE</given-names></name><name><surname>Davisson</surname><given-names>MT</given-names></name><name><surname>Nusinowitz</surname><given-names>S</given-names></name><name><surname>Heckenlively</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Retinal degeneration mutants in the mouse</article-title><source>Vision Research</source><volume>42</volume><fpage>517</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1016/s0042-6989(01)00146-8</pub-id><pub-id pub-id-type="pmid">11853768</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Hurd</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Nishina</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Survey of common eye diseases in laboratory mouse strains</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>54</volume><fpage>4974</fpage><lpage>4981</lpage><pub-id pub-id-type="doi">10.1167/iovs.13-12289</pub-id><pub-id pub-id-type="pmid">23800770</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarner</surname><given-names>T</given-names></name><name><surname>Janssen</surname><given-names>K</given-names></name><name><surname>Nellessen</surname><given-names>L</given-names></name><name><surname>Stangel</surname><given-names>M</given-names></name><name><surname>Skripuletz</surname><given-names>T</given-names></name><name><surname>Krauspe</surname><given-names>B</given-names></name><name><surname>Hess</surname><given-names>FM</given-names></name><name><surname>Denecke</surname><given-names>B</given-names></name><name><surname>Beutner</surname><given-names>C</given-names></name><name><surname>Linnartz-Gerlach</surname><given-names>B</given-names></name><name><surname>Neumann</surname><given-names>H</given-names></name><name><surname>Vallières</surname><given-names>L</given-names></name><name><surname>Amor</surname><given-names>S</given-names></name><name><surname>Ohl</surname><given-names>K</given-names></name><name><surname>Tenbrock</surname><given-names>K</given-names></name><name><surname>Beyer</surname><given-names>C</given-names></name><name><surname>Kipp</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CXCL10 triggers early microglial activation in the cuprizone model</article-title><source>Journal of Immunology</source><volume>194</volume><fpage>3400</fpage><lpage>3413</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1401459</pub-id><pub-id pub-id-type="pmid">25725102</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Combadière</surname><given-names>C</given-names></name><name><surname>Feumi</surname><given-names>C</given-names></name><name><surname>Raoul</surname><given-names>W</given-names></name><name><surname>Keller</surname><given-names>N</given-names></name><name><surname>Rodéro</surname><given-names>M</given-names></name><name><surname>Pézard</surname><given-names>A</given-names></name><name><surname>Lavalette</surname><given-names>S</given-names></name><name><surname>Houssier</surname><given-names>M</given-names></name><name><surname>Jonet</surname><given-names>L</given-names></name><name><surname>Picard</surname><given-names>E</given-names></name><name><surname>Debré</surname><given-names>P</given-names></name><name><surname>Sirinyan</surname><given-names>M</given-names></name><name><surname>Deterre</surname><given-names>P</given-names></name><name><surname>Ferroukhi</surname><given-names>T</given-names></name><name><surname>Cohen</surname><given-names>SY</given-names></name><name><surname>Chauvaud</surname><given-names>D</given-names></name><name><surname>Jeanny</surname><given-names>JC</given-names></name><name><surname>Chemtob</surname><given-names>S</given-names></name><name><surname>Behar-Cohen</surname><given-names>F</given-names></name><name><surname>Sennlaub</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration</article-title><source>The Journal of Clinical Investigation</source><volume>117</volume><fpage>2920</fpage><lpage>2928</lpage><pub-id pub-id-type="doi">10.1172/JCI31692</pub-id><pub-id pub-id-type="pmid">17909628</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costantini</surname><given-names>A</given-names></name><name><surname>Viola</surname><given-names>N</given-names></name><name><surname>Berretta</surname><given-names>A</given-names></name><name><surname>Galeazzi</surname><given-names>R</given-names></name><name><surname>Matacchione</surname><given-names>G</given-names></name><name><surname>Sabbatinelli</surname><given-names>J</given-names></name><name><surname>Storci</surname><given-names>G</given-names></name><name><surname>De Matteis</surname><given-names>S</given-names></name><name><surname>Butini</surname><given-names>L</given-names></name><name><surname>Rippo</surname><given-names>MR</given-names></name><name><surname>Procopio</surname><given-names>AD</given-names></name><name><surname>Caraceni</surname><given-names>D</given-names></name><name><surname>Antonicelli</surname><given-names>R</given-names></name><name><surname>Olivieri</surname><given-names>F</given-names></name><name><surname>Bonafè</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals</article-title><source>Aging</source><volume>10</volume><fpage>1268</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.18632/aging.101465</pub-id><pub-id pub-id-type="pmid">29885276</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coughlin</surname><given-names>BA</given-names></name><name><surname>Feenstra</surname><given-names>DJ</given-names></name><name><surname>Mohr</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Müller cells and diabetic retinopathy</article-title><source>Vision Research</source><volume>139</volume><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.visres.2017.03.013</pub-id><pub-id pub-id-type="pmid">28866025</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz-Guilloty</surname><given-names>F</given-names></name><name><surname>Saeed</surname><given-names>AM</given-names></name><name><surname>Echegaray</surname><given-names>JJ</given-names></name><name><surname>Duffort</surname><given-names>S</given-names></name><name><surname>Ballmick</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Betancourt</surname><given-names>M</given-names></name><name><surname>Viteri</surname><given-names>E</given-names></name><name><surname>Ramkhellawan</surname><given-names>GC</given-names></name><name><surname>Ewald</surname><given-names>E</given-names></name><name><surname>Feuer</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Wen</surname><given-names>R</given-names></name><name><surname>Hong</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Laird</surname><given-names>JM</given-names></name><name><surname>Sene</surname><given-names>A</given-names></name><name><surname>Apte</surname><given-names>RS</given-names></name><name><surname>Salomon</surname><given-names>RG</given-names></name><name><surname>Hollyfield</surname><given-names>JG</given-names></name><name><surname>Perez</surname><given-names>VL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Infiltration of Proinflammatory M1 Macrophages into the Outer Retina Precedes Damage in a Mouse Model of Age-Related Macular Degeneration</article-title><source>International Journal of Inflammation</source><volume>2013</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1155/2013/503725</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Sheng</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Identification of inflammatory mediators in patients with rhegmatogenous retinal detachment associated with choroidal detachment</article-title><source>Molecular Vision</source><volume>21</volume><fpage>417</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">26015767</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y-K</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z-C</given-names></name><name><surname>Long</surname><given-names>X-B</given-names></name><name><surname>Chen</surname><given-names>C-L</given-names></name><name><surname>Feng</surname><given-names>Q-M</given-names></name><name><surname>Zhang</surname><given-names>X-H</given-names></name><name><surname>Zeng</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hemokinin-1 stimulates C-C motif chemokine ligand 24 production in macrophages to enhance eosinophilic inflammation in nasal polyps</article-title><source>International Forum of Allergy &amp; Rhinology</source><volume>9</volume><fpage>1334</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.1002/alr.22430</pub-id><pub-id pub-id-type="pmid">31545881</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-asrar</surname><given-names>AMA</given-names></name><name><surname>Berghmans</surname><given-names>N</given-names></name><name><surname>Al-obeidan</surname><given-names>SA</given-names></name><name><surname>Gikandi</surname><given-names>PW</given-names></name><name><surname>Opdenakker</surname><given-names>G</given-names></name><name><surname>Van</surname><given-names>DJ</given-names></name><name><surname>Struyf</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The CC chemokines CCL8, CCL13 and CCL20 are local inflammatory biomarkers of HLA-B27- associated uveitis</article-title><source>Acta Ophthalmologica</source><volume>97</volume><fpage>e122</fpage><lpage>e128</lpage><pub-id pub-id-type="doi">10.1111/aos.13835</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbaz-Hayoun</surname><given-names>S</given-names></name><name><surname>Rinsky</surname><given-names>B</given-names></name><name><surname>Hagbi-Levi</surname><given-names>S</given-names></name><name><surname>Grunin</surname><given-names>M</given-names></name><collab>Tammy HayaYedid</collab><name><surname>Chowers</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Evaluation of antioxidant treatments for the modulation of macrophage function in the context of retinal degeneration</article-title><source>Molecular Vision</source><volume>25</volume><fpage>479</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">31588172</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faura</surname><given-names>J</given-names></name><name><surname>Bustamante</surname><given-names>A</given-names></name><name><surname>Penalba</surname><given-names>A</given-names></name><name><surname>Giralt</surname><given-names>D</given-names></name><name><surname>Simats</surname><given-names>A</given-names></name><name><surname>Martínez-Sáez</surname><given-names>E</given-names></name><name><surname>Alcolea</surname><given-names>D</given-names></name><name><surname>Fortea</surname><given-names>J</given-names></name><name><surname>Lleó</surname><given-names>A</given-names></name><name><surname>Teunissen</surname><given-names>CE</given-names></name><name><surname>van der Flier</surname><given-names>WM</given-names></name><name><surname>Ibañez</surname><given-names>L</given-names></name><name><surname>Harari</surname><given-names>O</given-names></name><name><surname>Cruchaga</surname><given-names>C</given-names></name><name><surname>Hernández-Guillamón</surname><given-names>M</given-names></name><name><surname>Delgado</surname><given-names>P</given-names></name><name><surname>Montaner</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer’s Disease</article-title><source>Journal of Alzheimer’s Disease</source><volume>73</volume><fpage>1585</fpage><lpage>1595</lpage><pub-id pub-id-type="doi">10.3233/JAD-190753</pub-id><pub-id pub-id-type="pmid">31958084</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>DS</given-names></name><name><surname>O’Colmain</surname><given-names>BJ</given-names></name><name><surname>Muñoz</surname><given-names>B</given-names></name><name><surname>Tomany</surname><given-names>SC</given-names></name><name><surname>McCarty</surname><given-names>C</given-names></name><name><surname>de Jong</surname><given-names>P</given-names></name><name><surname>Nemesure</surname><given-names>B</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Kempen</surname><given-names>J</given-names></name><collab>Eye Diseases Prevalence Research Group</collab></person-group><year iso-8601-date="2004">2004</year><article-title>Prevalence of age-related macular degeneration in the United States</article-title><source>Archives of Ophthalmology</source><volume>122</volume><fpage>564</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1001/archopht.122.4.564</pub-id><pub-id pub-id-type="pmid">15078675</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuichi</surname><given-names>K</given-names></name><name><surname>Gao</surname><given-names>JL</given-names></name><name><surname>Horuk</surname><given-names>R</given-names></name><name><surname>Wada</surname><given-names>T</given-names></name><name><surname>Kaneko</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury</article-title><source>Journal of Immunology</source><volume>181</volume><fpage>8670</fpage><lpage>8676</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.12.8670</pub-id><pub-id pub-id-type="pmid">19050287</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gale</surname><given-names>JD</given-names></name><name><surname>Berger</surname><given-names>B</given-names></name><name><surname>Gilbert</surname><given-names>S</given-names></name><name><surname>Popa</surname><given-names>S</given-names></name><name><surname>Sultan</surname><given-names>MB</given-names></name><name><surname>Schachar</surname><given-names>RA</given-names></name><name><surname>Girgenti</surname><given-names>D</given-names></name><name><surname>Perros-Huguet</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>59</volume><fpage>2659</fpage><lpage>2669</lpage><pub-id pub-id-type="doi">10.1167/iovs.17-22731</pub-id><pub-id pub-id-type="pmid">29847672</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>JL</given-names></name><name><surname>Kuhns</surname><given-names>DB</given-names></name><name><surname>Tiffany</surname><given-names>HL</given-names></name><name><surname>McDermott</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Francke</surname><given-names>U</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor</article-title><source>The Journal of Experimental Medicine</source><volume>177</volume><fpage>1421</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.1084/jem.177.5.1421</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>JL</given-names></name><name><surname>Wynn</surname><given-names>TA</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Broxmeyer</surname><given-names>HE</given-names></name><name><surname>Cooper</surname><given-names>S</given-names></name><name><surname>Tiffany</surname><given-names>HL</given-names></name><name><surname>Westphal</surname><given-names>H</given-names></name><name><surname>Kwon-Chung</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1</article-title><source>The Journal of Experimental Medicine</source><volume>185</volume><fpage>1959</fpage><lpage>1968</lpage><pub-id pub-id-type="doi">10.1084/jem.185.11.1959</pub-id><pub-id pub-id-type="pmid">9166425</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelinas</surname><given-names>L</given-names></name><name><surname>Falkenham</surname><given-names>A</given-names></name><name><surname>Oxner</surname><given-names>A</given-names></name><name><surname>Sopel</surname><given-names>M</given-names></name><name><surname>Légaré</surname><given-names>J-F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Highly purified human peripheral blood monocytes produce IL-6 but not TNFalpha in response to angiotensin II</article-title><source>Journal of the Renin-Angiotensin-Aldosterone System</source><volume>12</volume><fpage>295</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1177/1470320310391332</pub-id><pub-id pub-id-type="pmid">21393356</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gladue</surname><given-names>RP</given-names></name><name><surname>Brown</surname><given-names>MF</given-names></name><name><surname>Zwillich</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CCR1 antagonists: what have we learned from clinical trials</article-title><source>Current Topics in Medicinal Chemistry</source><volume>10</volume><fpage>1268</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.2174/156802610791561237</pub-id><pub-id pub-id-type="pmid">20536425</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimm</surname><given-names>C</given-names></name><name><surname>Remé</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Light damage as a model of retinal degeneration</article-title><source>Methods in Molecular Biology</source><volume>935</volume><fpage>87</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1007/978-1-62703-080-9_6</pub-id><pub-id pub-id-type="pmid">23150362</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunin</surname><given-names>M</given-names></name><name><surname>Burstyn-Cohen</surname><given-names>T</given-names></name><name><surname>Hagbi-Levi</surname><given-names>S</given-names></name><name><surname>Peled</surname><given-names>A</given-names></name><name><surname>Chowers</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Chemokine receptor expression in peripheral blood monocytes from patients with neovascular age-related macular degeneration</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>53</volume><fpage>5292</fpage><lpage>5300</lpage><pub-id pub-id-type="doi">10.1167/iovs.11-9165</pub-id><pub-id pub-id-type="pmid">22789920</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>BJ</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Avula</surname><given-names>PK</given-names></name><name><surname>Caruso</surname><given-names>E</given-names></name><name><surname>Drysdale</surname><given-names>C</given-names></name><name><surname>Vessey</surname><given-names>KA</given-names></name><name><surname>Ou</surname><given-names>A</given-names></name><name><surname>Fowler</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>T-H</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Horton</surname><given-names>A</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Wiley</surname><given-names>JS</given-names></name><name><surname>Guymer</surname><given-names>RH</given-names></name><name><surname>Fletcher</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Deficits in monocyte function in age related macular degeneration: A novel systemic change associated with the disease</article-title><source>Frontiers in Medicine</source><volume>8</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.3389/fmed.2021.634177</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagbi-Levi</surname><given-names>S</given-names></name><name><surname>Grunin</surname><given-names>M</given-names></name><name><surname>Jaouni</surname><given-names>T</given-names></name><name><surname>Tiosano</surname><given-names>L</given-names></name><name><surname>Rinsky</surname><given-names>B</given-names></name><name><surname>Elbaz-Hayoun</surname><given-names>S</given-names></name><name><surname>Peled</surname><given-names>A</given-names></name><name><surname>Chowers</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Proangiogenic characteristics of activated macrophages from patients with age-related macular degeneration</article-title><source>Neurobiology of Aging</source><volume>51</volume><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.11.018</pub-id><pub-id pub-id-type="pmid">28039766</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horuk</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Chemokine receptors</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>12</volume><fpage>313</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/s1359-6101(01)00014-4</pub-id><pub-id pub-id-type="pmid">11544102</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Leak</surname><given-names>RK</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Suenaga</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Microglial and macrophage polarization—new prospects for brain repair</article-title><source>Nature Reviews. Neurology</source><volume>11</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2014.207</pub-id><pub-id pub-id-type="pmid">25385337</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>H</given-names></name><name><surname>Natoli</surname><given-names>R</given-names></name><name><surname>Valter</surname><given-names>K</given-names></name><name><surname>Provis</surname><given-names>JM</given-names></name><name><surname>Rutar</surname><given-names>M</given-names></name><name><surname>Lewin</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Spatiotemporal cadence of macrophage polarisation in a model of light-induced retinal degeneration</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0143952</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0143952</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joachim</surname><given-names>N</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Burlutsky</surname><given-names>G</given-names></name><name><surname>Kifley</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The incidence and progression of age-related macular degeneration over 15 years: The blue mountains eye study</article-title><source>Ophthalmology</source><volume>122</volume><fpage>2482</fpage><lpage>2489</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2015.08.002</pub-id><pub-id pub-id-type="pmid">26383995</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joo</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Shin</surname><given-names>JH</given-names></name><name><surname>Moon</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Aqueous humor cytokine levels through microarray analysis and a sub-analysis based on optical coherence tomography in wet age-related macular degeneration patients</article-title><source>BMC Ophthalmology</source><volume>21</volume><elocation-id>399</elocation-id><pub-id pub-id-type="doi">10.1186/s12886-021-02152-6</pub-id><pub-id pub-id-type="pmid">34794403</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadomoto</surname><given-names>S</given-names></name><name><surname>Izumi</surname><given-names>K</given-names></name><name><surname>Mizokami</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Macrophage polarity and disease control</article-title><source>International Journal of Molecular Sciences</source><volume>23</volume><elocation-id>144</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23010144</pub-id><pub-id pub-id-type="pmid">35008577</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>J</given-names></name><name><surname>Ali Khan</surname><given-names>A</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Ferguson</surname><given-names>TA</given-names></name><name><surname>Apte</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice</article-title><source>The Journal of Clinical Investigation</source><volume>117</volume><fpage>3421</fpage><lpage>3426</lpage><pub-id pub-id-type="doi">10.1172/JCI32430</pub-id><pub-id pub-id-type="pmid">17975672</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lad</surname><given-names>EM</given-names></name><name><surname>Cousins</surname><given-names>SW</given-names></name><name><surname>Van Arnam</surname><given-names>JS</given-names></name><name><surname>Proia</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Abundance of infiltrating CD163+ cells in the retina of postmortem eyes with dry and neovascular age-related macular degeneration</article-title><source>Graefe’s Archive for Clinical and Experimental Ophthalmology</source><volume>253</volume><fpage>1941</fpage><lpage>1945</lpage><pub-id pub-id-type="doi">10.1007/s00417-015-3094-z</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lederman</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Chowers</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Association of neovascular age-related macular degeneration with specific gene expression patterns in peripheral white blood cells</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>51</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1167/iovs.08-3019</pub-id><pub-id pub-id-type="pmid">19684010</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leeuwen</surname><given-names>RV</given-names></name><name><surname>Klaver</surname><given-names>CCW</given-names></name><name><surname>Vingerling</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The risk and natural course of age-related maculopathy</article-title><source>Archives of Ophthalmology</source><volume>121</volume><elocation-id>519</elocation-id><pub-id pub-id-type="doi">10.1001/archopht.121.4.519</pub-id><pub-id pub-id-type="pmid">12695249</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>CE</given-names></name><name><surname>Pollard</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Distinct role of macrophages in different tumor microenvironments</article-title><source>Cancer Research</source><volume>66</volume><fpage>605</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4005</pub-id><pub-id pub-id-type="pmid">16423985</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>M</given-names></name><name><surname>Mallari</surname><given-names>C</given-names></name><name><surname>Rosser</surname><given-names>M</given-names></name><name><surname>Ng</surname><given-names>HP</given-names></name><name><surname>May</surname><given-names>K</given-names></name><name><surname>Monahan</surname><given-names>S</given-names></name><name><surname>Bauman</surname><given-names>JG</given-names></name><name><surname>Islam</surname><given-names>I</given-names></name><name><surname>Ghannam</surname><given-names>A</given-names></name><name><surname>Buckman</surname><given-names>B</given-names></name><name><surname>Shaw</surname><given-names>K</given-names></name><name><surname>Wei</surname><given-names>GP</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Ho</surname><given-names>E</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Oanh</surname><given-names>H</given-names></name><name><surname>Subramanyam</surname><given-names>B</given-names></name><name><surname>Vergona</surname><given-names>R</given-names></name><name><surname>Taub</surname><given-names>D</given-names></name><name><surname>Dunning</surname><given-names>L</given-names></name><name><surname>Harvey</surname><given-names>S</given-names></name><name><surname>Snider</surname><given-names>RM</given-names></name><name><surname>Hesselgesser</surname><given-names>J</given-names></name><name><surname>Morrissey</surname><given-names>MM</given-names></name><name><surname>Perez</surname><given-names>HD</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>19000</fpage><lpage>19008</lpage><pub-id pub-id-type="doi">10.1074/jbc.M001222200</pub-id><pub-id pub-id-type="pmid">10748002</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>A</given-names></name><name><surname>Zhan</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Aqueous humor cytokine profiling in patients with wet AMD</article-title><source>Molecular Vision</source><volume>22</volume><fpage>352</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">27122966</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lückoff</surname><given-names>A</given-names></name><name><surname>Scholz</surname><given-names>R</given-names></name><name><surname>Sennlaub</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Langmann</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Comprehensive analysis of mouse retinal mononuclear phagocytes</article-title><source>Nature Protocols</source><volume>12</volume><fpage>1136</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1038/nprot.2017.032</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Sozzani</surname><given-names>S</given-names></name><name><surname>Locati</surname><given-names>M</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes</article-title><source>Trends in Immunology</source><volume>23</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/S1471-4906(02)02302-5</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Sozzani</surname><given-names>S</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Vecchi</surname><given-names>A</given-names></name><name><surname>Locati</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The chemokine system in diverse forms of macrophage activation and polarization</article-title><source>Trends in Immunology</source><volume>25</volume><fpage>677</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1016/j.it.2004.09.015</pub-id><pub-id pub-id-type="pmid">15530839</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Bonecchi</surname><given-names>R</given-names></name><name><surname>Locati</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Tuning inflammation and immunity by chemokine sequestration: decoys and more</article-title><source>Nature Reviews Immunology</source><volume>6</volume><fpage>907</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1038/nri1964</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>FO</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Locati</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Macrophage activation and polarization</article-title><source>Frontiers in Bioscience</source><volume>13</volume><fpage>453</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.2741/2692</pub-id><pub-id pub-id-type="pmid">17981560</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>FO</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The transcriptome of human monocyte subsets begins to emerge</article-title><source>Journal of Biology</source><volume>8</volume><elocation-id>99</elocation-id><pub-id pub-id-type="doi">10.1186/jbiol206</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>FO</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The M1 and M2 paradigm of macrophage activation: time for reassessment</article-title><source>F1000prime Reports</source><volume>6</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.12703/P6-13</pub-id><pub-id pub-id-type="pmid">24669294</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massengill</surname><given-names>MT</given-names></name><name><surname>Ahmed</surname><given-names>CM</given-names></name><name><surname>Lewin</surname><given-names>AS</given-names></name><name><surname>Ildefonso</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Neuroinflammation in retinitis pigmentosa, diabetic retinopathy, and age-related macular degeneration: A minireview</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1074</volume><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-75402-4_23</pub-id><pub-id pub-id-type="pmid">29721943</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>H</given-names></name><name><surname>Sugio</surname><given-names>S</given-names></name><name><surname>Seghers</surname><given-names>F</given-names></name><name><surname>Krizaj</surname><given-names>D</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Ishizaki</surname><given-names>Y</given-names></name><name><surname>Gailly</surname><given-names>P</given-names></name><name><surname>Shibasaki</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Retinal Detachment-Induced Müller Glial Cell Swelling Activates TRPV4 Ion Channels and Triggers Photoreceptor Death at Body Temperature</article-title><source>The Journal of Neuroscience</source><volume>38</volume><fpage>8745</fpage><lpage>8758</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0897-18.2018</pub-id><pub-id pub-id-type="pmid">30143574</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattapallil</surname><given-names>MJ</given-names></name><name><surname>Wawrousek</surname><given-names>EF</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Roychoudhury</surname><given-names>J</given-names></name><name><surname>Ferguson</surname><given-names>TA</given-names></name><name><surname>Caspi</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The Rd8 mutation of the Crb1 gene is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>53</volume><fpage>2921</fpage><lpage>2927</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-9662</pub-id><pub-id pub-id-type="pmid">22447858</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McWhorter</surname><given-names>FY</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>P</given-names></name><name><surname>Chung</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>WF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Modulation of macrophage phenotype by cell shape</article-title><source>PNAS</source><volume>110</volume><fpage>17253</fpage><lpage>17258</lpage><pub-id pub-id-type="doi">10.1073/pnas.1308887110</pub-id><pub-id pub-id-type="pmid">24101477</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendez-Enriquez</surname><given-names>E</given-names></name><name><surname>García-Zepeda</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The multiple faces of CCL13 in immunity and inflammation</article-title><source>Inflammopharmacology</source><volume>21</volume><fpage>397</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1007/s10787-013-0177-5</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Méndez-Enríquez</surname><given-names>E</given-names></name><name><surname>Medina-Tamayo</surname><given-names>J</given-names></name><name><surname>Soldevila</surname><given-names>G</given-names></name><name><surname>Fortoul</surname><given-names>TI</given-names></name><name><surname>Anton</surname><given-names>B</given-names></name><name><surname>Flores-Romo</surname><given-names>L</given-names></name><name><surname>García-Zepeda</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A CCL chemokine-derived peptide (CDIP-2) exerts anti-inflammatory activity via CCR1, CCR2 and CCR3 chemokine receptors: Implications as A potential therapeutic treatment of asthma</article-title><source>International Immunopharmacology</source><volume>20</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2014.01.032</pub-id><pub-id pub-id-type="pmid">24560857</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>M1 and M2 Macrophages: Oracles of Health and Disease</article-title><source>Critical Reviews in Immunology</source><volume>32</volume><fpage>463</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1615/critrevimmunol.v32.i6.10</pub-id><pub-id pub-id-type="pmid">23428224</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mor</surname><given-names>A</given-names></name><name><surname>Segal Salto</surname><given-names>M</given-names></name><name><surname>Katav</surname><given-names>A</given-names></name><name><surname>Barashi</surname><given-names>N</given-names></name><name><surname>Edelshtein</surname><given-names>V</given-names></name><name><surname>Manetti</surname><given-names>M</given-names></name><name><surname>Levi</surname><given-names>Y</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Matucci-Cerinic</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis</article-title><source>Annals of the Rheumatic Diseases</source><volume>78</volume><fpage>1260</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2019-215119</pub-id><pub-id pub-id-type="pmid">31129606</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>R</given-names></name><name><surname>Sene</surname><given-names>A</given-names></name><name><surname>Santeford</surname><given-names>A</given-names></name><name><surname>Gdoura</surname><given-names>A</given-names></name><name><surname>Kubota</surname><given-names>S</given-names></name><name><surname>Zapata</surname><given-names>N</given-names></name><name><surname>Apte</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>IL10-driven STAT3 signalling in senescent macrophages promotes pathological eye angiogenesis</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7847</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8847</pub-id><pub-id pub-id-type="pmid">26260587</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>T</given-names></name><name><surname>Hisatomi</surname><given-names>T</given-names></name><name><surname>Nakazawa</surname><given-names>C</given-names></name><name><surname>Noda</surname><given-names>K</given-names></name><name><surname>Maruyama</surname><given-names>K</given-names></name><name><surname>She</surname><given-names>H</given-names></name><name><surname>Matsubara</surname><given-names>A</given-names></name><name><surname>Miyahara</surname><given-names>S</given-names></name><name><surname>Nakao</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Benowitz</surname><given-names>L</given-names></name><name><surname>Hafezi-Moghadam</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Monocyte chemoattractant protein 1 mediates retinal detachment-induced photoreceptor apoptosis</article-title><source>PNAS</source><volume>104</volume><fpage>2425</fpage><lpage>2430</lpage><pub-id pub-id-type="doi">10.1073/pnas.0608167104</pub-id><pub-id pub-id-type="pmid">17284607</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Treatment for rheumatoid arthritis by chemokine blockade</article-title><source>Japanese Journal of Clinical Immunology</source><volume>39</volume><fpage>172</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.2177/jsci.39.172</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>C</given-names></name><name><surname>Ding</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Nonresolving inflammation</article-title><source>Cell</source><volume>140</volume><fpage>871</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.02.029</pub-id><pub-id pub-id-type="pmid">20303877</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natoli</surname><given-names>R</given-names></name><name><surname>Fernando</surname><given-names>N</given-names></name><name><surname>Madigan</surname><given-names>M</given-names></name><name><surname>Chu-Tan</surname><given-names>JA</given-names></name><name><surname>Valter</surname><given-names>K</given-names></name><name><surname>Provis</surname><given-names>J</given-names></name><name><surname>Rutar</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Microglia-derived IL-1β promotes chemokine expression by Müller cells and RPE in focal retinal degeneration</article-title><source>Molecular Neurodegeneration</source><volume>12</volume><elocation-id>31</elocation-id><pub-id pub-id-type="doi">10.1186/s13024-017-0175-y</pub-id><pub-id pub-id-type="pmid">28438165</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Da</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Neuroprotective effects of naloxone against light-induced photoreceptor degeneration through inhibiting retinal microglial activation</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>49</volume><fpage>2589</fpage><lpage>2598</lpage><pub-id pub-id-type="doi">10.1167/iovs.07-1173</pub-id><pub-id pub-id-type="pmid">18515588</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozawa</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Oxidative stress in the light-exposed retina and its implication in age-related macular degeneration</article-title><source>Redox Biology</source><volume>37</volume><elocation-id>101779</elocation-id><pub-id pub-id-type="doi">10.1016/j.redox.2020.101779</pub-id><pub-id pub-id-type="pmid">33172789</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelegrin</surname><given-names>P</given-names></name><name><surname>Surprenant</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates</article-title><source>The EMBO Journal</source><volume>28</volume><fpage>2114</fpage><lpage>2127</lpage><pub-id pub-id-type="doi">10.1038/emboj.2009.163</pub-id><pub-id pub-id-type="pmid">19536133</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penfold</surname><given-names>PL</given-names></name><name><surname>Madigan</surname><given-names>MC</given-names></name><name><surname>Gillies</surname><given-names>MC</given-names></name><name><surname>Provis</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Immunological and aetiological aspects of macular degeneration</article-title><source>Progress in Retinal and Eye Research</source><volume>20</volume><fpage>385</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/s1350-9462(00)00025-2</pub-id><pub-id pub-id-type="pmid">11286898</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portillo</surname><given-names>J-AC</given-names></name><name><surname>Greene</surname><given-names>JA</given-names></name><name><surname>Okenka</surname><given-names>G</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Sheibani</surname><given-names>N</given-names></name><name><surname>Kern</surname><given-names>TS</given-names></name><name><surname>Subauste</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CD40 promotes the development of early diabetic retinopathy in mice</article-title><source>Diabetologia</source><volume>57</volume><fpage>2222</fpage><lpage>2231</lpage><pub-id pub-id-type="doi">10.1007/s00125-014-3321-x</pub-id><pub-id pub-id-type="pmid">25015056</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portillo</surname><given-names>J-AC</given-names></name><name><surname>Lopez Corcino</surname><given-names>Y</given-names></name><name><surname>Dubyak</surname><given-names>GR</given-names></name><name><surname>Kern</surname><given-names>TS</given-names></name><name><surname>Matsuyama</surname><given-names>S</given-names></name><name><surname>Subauste</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ligation of CD40 in Human Müller Cells Induces P2X7 Receptor-Dependent Death of Retinal Endothelial Cells</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>57</volume><fpage>6278</fpage><lpage>6286</lpage><pub-id pub-id-type="doi">10.1167/iovs.16-20301</pub-id><pub-id pub-id-type="pmid">27893093</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portillo</surname><given-names>J-AC</given-names></name><name><surname>Lopez Corcino</surname><given-names>Y</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Sheibani</surname><given-names>N</given-names></name><name><surname>Kern</surname><given-names>TS</given-names></name><name><surname>Dubyak</surname><given-names>GR</given-names></name><name><surname>Subauste</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CD40 in Retinal Müller Cells Induces P2X7-Dependent Cytokine Expression in Macrophages/Microglia in Diabetic Mice and Development of Early Experimental Diabetic Retinopathy</article-title><source>Diabetes</source><volume>66</volume><fpage>483</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.2337/db16-0051</pub-id><pub-id pub-id-type="pmid">27474370</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raoul</surname><given-names>W</given-names></name><name><surname>Auvynet</surname><given-names>C</given-names></name><name><surname>Camelo</surname><given-names>S</given-names></name><name><surname>Guillonneau</surname><given-names>X</given-names></name><name><surname>Feumi</surname><given-names>C</given-names></name><name><surname>Combadière</surname><given-names>C</given-names></name><name><surname>Sennlaub</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration</article-title><source>Journal of Neuroinflammation</source><volume>7</volume><elocation-id>87</elocation-id><pub-id pub-id-type="doi">10.1186/1742-2094-7-87</pub-id><pub-id pub-id-type="pmid">21126357</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichenbach</surname><given-names>A</given-names></name><name><surname>Bringmann</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>New functions of Müller cells</article-title><source>Glia</source><volume>61</volume><fpage>651</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1002/glia.22477</pub-id><pub-id pub-id-type="pmid">23440929</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Resnikoff</surname><given-names>S</given-names></name><name><surname>Pascolini</surname><given-names>D</given-names></name><name><surname>Etya’ale</surname><given-names>D</given-names></name><name><surname>Kocur</surname><given-names>I</given-names></name><name><surname>Pararajasegaram</surname><given-names>R</given-names></name><name><surname>Pokharel</surname><given-names>GP</given-names></name><name><surname>Mariotti</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Global data on visual impairment in the year 2002</article-title><source>Bulletin of the World Health Organization</source><volume>82</volume><fpage>844</fpage><lpage>851</lpage><pub-id pub-id-type="pmid">15640920</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenfeld</surname><given-names>PJ</given-names></name><name><surname>Brown</surname><given-names>DM</given-names></name><name><surname>Heier</surname><given-names>JS</given-names></name><name><surname>Boyer</surname><given-names>DS</given-names></name><name><surname>Kaiser</surname><given-names>PK</given-names></name><name><surname>Chung</surname><given-names>CY</given-names></name><name><surname>Kim</surname><given-names>RY</given-names></name><collab>MARINA Study Group</collab></person-group><year iso-8601-date="2006">2006</year><article-title>Ranibizumab for neovascular age-related macular degeneration</article-title><source>The New England Journal of Medicine</source><volume>355</volume><fpage>1419</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa054481</pub-id><pub-id pub-id-type="pmid">17021318</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutar</surname><given-names>M</given-names></name><name><surname>Natoli</surname><given-names>R</given-names></name><name><surname>Provis</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Small interfering RNA-mediated suppression of Ccl2 in Müller cells attenuates microglial recruitment and photoreceptor death following retinal degeneration</article-title><source>Journal of Neuroinflammation</source><volume>9</volume><elocation-id>221</elocation-id><pub-id pub-id-type="doi">10.1186/1742-2094-9-221</pub-id><pub-id pub-id-type="pmid">22992301</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutar</surname><given-names>M</given-names></name><name><surname>Natoli</surname><given-names>R</given-names></name><name><surname>Chia</surname><given-names>RX</given-names></name><name><surname>Valter</surname><given-names>K</given-names></name><name><surname>Provis</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chemokine-mediated inflammation in the degenerating retina is coordinated by Müller cells, activated microglia, and retinal pigment epithelium</article-title><source>Journal of Neuroinflammation</source><volume>12</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.1186/s12974-014-0224-1</pub-id><pub-id pub-id-type="pmid">25595590</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saddala</surname><given-names>MS</given-names></name><name><surname>Lennikov</surname><given-names>A</given-names></name><name><surname>Mukwaya</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transcriptome-wide analysis of differentially expressed chemokine receptors, SNPs, and SSRs in the age-related macular degeneration</article-title><source>Human Genomics</source><volume>13</volume><elocation-id>15</elocation-id><pub-id pub-id-type="doi">10.1186/s40246-019-0199-1</pub-id><pub-id pub-id-type="pmid">30894217</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santella</surname><given-names>JB</given-names></name><name><surname>Gardner</surname><given-names>DS</given-names></name><name><surname>Duncia</surname><given-names>JV</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Dhar</surname><given-names>M</given-names></name><name><surname>Cavallaro</surname><given-names>C</given-names></name><name><surname>Tebben</surname><given-names>AJ</given-names></name><name><surname>Carter</surname><given-names>PH</given-names></name><name><surname>Barrish</surname><given-names>JC</given-names></name><name><surname>Yarde</surname><given-names>M</given-names></name><name><surname>Briceno</surname><given-names>SW</given-names></name><name><surname>Cvijic</surname><given-names>ME</given-names></name><name><surname>Grafstrom</surname><given-names>RR</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>SR</given-names></name><name><surname>Watson</surname><given-names>AJ</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Rose</surname><given-names>AV</given-names></name><name><surname>Vickery</surname><given-names>RD</given-names></name><name><surname>Caceres-Cortes</surname><given-names>J</given-names></name><name><surname>Caporuscio</surname><given-names>C</given-names></name><name><surname>Camac</surname><given-names>DM</given-names></name><name><surname>Khan</surname><given-names>JA</given-names></name><name><surname>An</surname><given-names>Y</given-names></name><name><surname>Foster</surname><given-names>WR</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Hynes</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis</article-title><source>Journal of Medicinal Chemistry</source><volume>57</volume><fpage>7550</fpage><lpage>7564</lpage><pub-id pub-id-type="doi">10.1021/jm5003167</pub-id><pub-id pub-id-type="pmid">25101488</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sebastián</surname><given-names>C</given-names></name><name><surname>Lloberas</surname><given-names>J</given-names></name><name><surname>Celada</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><chapter-title>Molecular and cellular aspects of macrophage aging Springer</chapter-title><person-group person-group-type="editor"><name><surname>Fulop</surname><given-names>T</given-names></name><name><surname>Franceschi</surname><given-names>C</given-names></name><name><surname>Hirokawa</surname><given-names>K</given-names></name><name><surname>Pawelec</surname><given-names>G</given-names></name></person-group><source>Handbook on Immunosenescence</source><publisher-loc>Dordrecht</publisher-loc><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-1-4020-9063-9_46</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seddon</surname><given-names>JM</given-names></name><name><surname>Gensler</surname><given-names>G</given-names></name><name><surname>Milton</surname><given-names>RC</given-names></name><name><surname>Klein</surname><given-names>ML</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Association between C-reactive protein and age-related macular degeneration</article-title><source>JAMA</source><volume>291</volume><fpage>704</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1001/jama.291.6.704</pub-id><pub-id pub-id-type="pmid">14871913</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segal-Salto</surname><given-names>M</given-names></name><name><surname>Barashi</surname><given-names>N</given-names></name><name><surname>Katav</surname><given-names>A</given-names></name><name><surname>Edelshtein</surname><given-names>V</given-names></name><name><surname>Aharon</surname><given-names>A</given-names></name><name><surname>Hashmueli</surname><given-names>S</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Maor</surname><given-names>Y</given-names></name><name><surname>Pinzani</surname><given-names>M</given-names></name><name><surname>Haberman</surname><given-names>D</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name><name><surname>Friedman</surname><given-names>S</given-names></name><name><surname>Mor</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage</article-title><source>JHEP Reports</source><volume>2</volume><elocation-id>100064</elocation-id><pub-id pub-id-type="doi">10.1016/j.jhepr.2019.100064</pub-id><pub-id pub-id-type="pmid">32039405</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sene</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>AA</given-names></name><name><surname>Cox</surname><given-names>D</given-names></name><name><surname>Nakamura</surname><given-names>REI</given-names></name><name><surname>Santeford</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>BM</given-names></name><name><surname>Sidhu</surname><given-names>R</given-names></name><name><surname>Onken</surname><given-names>MD</given-names></name><name><surname>Harbour</surname><given-names>JW</given-names></name><name><surname>Hagbi-Levi</surname><given-names>S</given-names></name><name><surname>Chowers</surname><given-names>I</given-names></name><name><surname>Edwards</surname><given-names>PA</given-names></name><name><surname>Baldan</surname><given-names>A</given-names></name><name><surname>Parks</surname><given-names>JS</given-names></name><name><surname>Ory</surname><given-names>DS</given-names></name><name><surname>Apte</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration</article-title><source>Cell Metabolism</source><volume>17</volume><fpage>549</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.03.009</pub-id><pub-id pub-id-type="pmid">23562078</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sennlaub</surname><given-names>F</given-names></name><name><surname>Auvynet</surname><given-names>C</given-names></name><name><surname>Calippe</surname><given-names>B</given-names></name><name><surname>Lavalette</surname><given-names>S</given-names></name><name><surname>Poupel</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>SJ</given-names></name><name><surname>Dominguez</surname><given-names>E</given-names></name><name><surname>Camelo</surname><given-names>S</given-names></name><name><surname>Levy</surname><given-names>O</given-names></name><name><surname>Guyon</surname><given-names>E</given-names></name><name><surname>Saederup</surname><given-names>N</given-names></name><name><surname>Charo</surname><given-names>IF</given-names></name><name><surname>Rooijen</surname><given-names>NV</given-names></name><name><surname>Nandrot</surname><given-names>E</given-names></name><name><surname>Bourges</surname><given-names>J-L</given-names></name><name><surname>Behar-Cohen</surname><given-names>F</given-names></name><name><surname>Sahel</surname><given-names>J-A</given-names></name><name><surname>Guillonneau</surname><given-names>X</given-names></name><name><surname>Raoul</surname><given-names>W</given-names></name><name><surname>Combadiere</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CCR2(+) monocytes infiltrate atrophic lesions in age-related macular disease and mediate photoreceptor degeneration in experimental subretinal inflammation in Cx3cr1 deficient mice</article-title><source>EMBO Molecular Medicine</source><volume>5</volume><fpage>1775</fpage><lpage>1793</lpage><pub-id pub-id-type="doi">10.1002/emmm.201302692</pub-id><pub-id pub-id-type="pmid">24142887</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>NK</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Prabhakar</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Bhatt</surname><given-names>AK</given-names></name><name><surname>Anand</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CC chemokine receptor-3 as new target for age-related macular degeneration</article-title><source>Gene</source><volume>523</volume><fpage>106</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2013.03.052</pub-id><pub-id pub-id-type="pmid">23566847</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Tuo</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Naloxone ameliorates retinal lesions in Ccl2/Cx3cr1 double-deficient mice via modulation of microglia</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>52</volume><fpage>2897</fpage><lpage>2904</lpage><pub-id pub-id-type="doi">10.1167/iovs.10-6114</pub-id><pub-id pub-id-type="pmid">21245403</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoji</surname><given-names>J</given-names></name><name><surname>Aso</surname><given-names>H</given-names></name><name><surname>Inada</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Clinical usefulness of simultaneous measurement of the Tear Levels of CCL17, CCL24, and IL-16 for the Biomarkers of Allergic Conjunctival Disorders</article-title><source>Current Eye Research</source><volume>42</volume><fpage>677</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1080/02713683.2016.1242755</pub-id><pub-id pub-id-type="pmid">27897453</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Invernizzi</surname><given-names>P</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Macrophage plasticity and polarization in liver homeostasis and pathology</article-title><source>Hepatology</source><volume>59</volume><fpage>2034</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.1002/hep.26754</pub-id><pub-id pub-id-type="pmid">24115204</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simats</surname><given-names>A</given-names></name><name><surname>García-Berrocoso</surname><given-names>T</given-names></name><name><surname>Penalba</surname><given-names>A</given-names></name><name><surname>Giralt</surname><given-names>D</given-names></name><name><surname>Llovera</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Ramiro</surname><given-names>L</given-names></name><name><surname>Bustamante</surname><given-names>A</given-names></name><name><surname>Martinez-Saez</surname><given-names>E</given-names></name><name><surname>Canals</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liesz</surname><given-names>A</given-names></name><name><surname>Rosell</surname><given-names>A</given-names></name><name><surname>Montaner</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CCL23: a new CC chemokine involved in human brain damage</article-title><source>Journal of Internal Medicine</source><volume>283</volume><fpage>461</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1111/joim.12738</pub-id><pub-id pub-id-type="pmid">29415332</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>MA</given-names></name><name><surname>Awh</surname><given-names>CC</given-names></name><name><surname>Sadda</surname><given-names>S</given-names></name><name><surname>Freeman</surname><given-names>WR</given-names></name><name><surname>Antoszyk</surname><given-names>AN</given-names></name><name><surname>Wong</surname><given-names>P</given-names></name><name><surname>Tuomi</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration</article-title><source>Ophthalmology</source><volume>119</volume><fpage>1175</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2011.12.016</pub-id><pub-id pub-id-type="pmid">22306121</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smailhodzic</surname><given-names>D</given-names></name><name><surname>Muether</surname><given-names>PS</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Kwestro</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>AY</given-names></name><name><surname>Omar</surname><given-names>A</given-names></name><name><surname>Van de Ven</surname><given-names>JPH</given-names></name><name><surname>Keunen</surname><given-names>JEE</given-names></name><name><surname>Kirchhof</surname><given-names>B</given-names></name><name><surname>Hoyng</surname><given-names>CB</given-names></name><name><surname>Klevering</surname><given-names>BJ</given-names></name><name><surname>Koenekoop</surname><given-names>RK</given-names></name><name><surname>Fauser</surname><given-names>S</given-names></name><name><surname>den Hollander</surname><given-names>AI</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration</article-title><source>Ophthalmology</source><volume>119</volume><fpage>2304</fpage><lpage>2311</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2012.05.040</pub-id><pub-id pub-id-type="pmid">22840423</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Kawamura</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Puro</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Enhancement of P2X(7)-induced pore formation and apoptosis: an early effect of diabetes on the retinal microvasculature</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>45</volume><fpage>1026</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1167/iovs.03-1062</pub-id><pub-id pub-id-type="pmid">14985326</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Telegina</surname><given-names>DV</given-names></name><name><surname>Kozhevnikova</surname><given-names>OS</given-names></name><name><surname>Kolosova</surname><given-names>NG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Changes in retinal glial cells with age and during development of age-related macular degeneration</article-title><source>Biochemistry. Biokhimiia</source><volume>83</volume><fpage>1009</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1134/S000629791809002X</pub-id><pub-id pub-id-type="pmid">30472939</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trebst</surname><given-names>C</given-names></name><name><surname>Sorensen</surname><given-names>TL</given-names></name><name><surname>Kivisakk</surname><given-names>P</given-names></name><name><surname>Cathcart</surname><given-names>MK</given-names></name><name><surname>Hesselgesser</surname><given-names>J</given-names></name><name><surname>Horuk</surname><given-names>R</given-names></name><name><surname>Sellebjerg</surname><given-names>F</given-names></name><name><surname>Lassmann</surname><given-names>H</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Chemokine receptors on mononuclear phagocytes in the central nervous system of patients with multiple sclerosis</article-title><source>Ernst Scher Res Found Work</source><volume>39</volume><fpage>193</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1007/978-3-662-05073-6</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trummer</surname><given-names>D</given-names></name><name><surname>Walzer</surname><given-names>A</given-names></name><name><surname>Groettrup-Wolfers</surname><given-names>E</given-names></name><name><surname>Schmitz</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Efficacy, safety and tolerability of the CCR1 antagonist BAY 86-5047 for the treatment of endometriosis-associated pelvic pain: a randomized controlled trial</article-title><source>Acta Obstetricia et Gynecologica Scandinavica</source><volume>96</volume><fpage>694</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1111/aogs.13105</pub-id><pub-id pub-id-type="pmid">28168715</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsou</surname><given-names>CL</given-names></name><name><surname>Gladue</surname><given-names>RP</given-names></name><name><surname>Carroll</surname><given-names>LA</given-names></name><name><surname>Paradis</surname><given-names>T</given-names></name><name><surname>Boyd</surname><given-names>JG</given-names></name><name><surname>Nelson</surname><given-names>RT</given-names></name><name><surname>Neote</surname><given-names>K</given-names></name><name><surname>Charo</surname><given-names>IF</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Identification of C-C chemokine receptor 1 (CCR1) as the monocyte hemofiltrate C-C chemokine (HCC)-1 receptor</article-title><source>The Journal of Experimental Medicine</source><volume>188</volume><fpage>603</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1084/jem.188.3.603</pub-id><pub-id pub-id-type="pmid">9687537</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuo</surname><given-names>J</given-names></name><name><surname>Grob</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genetics of immunological and inflammatory components in age-related macular degeneration</article-title><source>Ocular Immunology and Inflammation</source><volume>20</volume><fpage>27</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.3109/09273948.2011.628432</pub-id><pub-id pub-id-type="pmid">22324898</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Fariss</surname><given-names>RN</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Adaptive Müller cell responses to microglial activation mediate neuroprotection and coordinate inflammation in the retina</article-title><source>Journal of Neuroinflammation</source><volume>8</volume><elocation-id>173</elocation-id><pub-id pub-id-type="doi">10.1186/1742-2094-8-173</pub-id><pub-id pub-id-type="pmid">22152278</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Koenig</surname><given-names>AL</given-names></name><name><surname>Lavine</surname><given-names>KJ</given-names></name><name><surname>Apte</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Macrophage plasticity and function in the eye and heart</article-title><source>Trends in Immunology</source><volume>40</volume><fpage>825</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1016/j.it.2019.07.002</pub-id><pub-id pub-id-type="pmid">31422901</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>A</given-names></name><name><surname>Grimm</surname><given-names>C</given-names></name><name><surname>Samardzija</surname><given-names>M</given-names></name><name><surname>Remé</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The genetic modifier Rpe65Leu(450): effect on light damage susceptibility in c-Fos-deficient mice</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>44</volume><fpage>2798</fpage><lpage>2802</lpage><pub-id pub-id-type="doi">10.1167/iovs.02-1134</pub-id><pub-id pub-id-type="pmid">12766089</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westenskow</surname><given-names>P</given-names></name><name><surname>Sedillo</surname><given-names>Z</given-names></name><name><surname>Barnett</surname><given-names>A</given-names></name><name><surname>Friedlander</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Efficient derivation of retinal pigment epithelium cells from stem cells</article-title><source>Journal of Visualized Experiments</source><fpage>25</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.3791/52214</pub-id><pub-id pub-id-type="pmid">25867641</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>WL</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Cheung</surname><given-names>CMG</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Cheng</surname><given-names>CY</given-names></name><name><surname>Wong</surname><given-names>TY</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis</article-title><source>The Lancet Global Health</source><volume>2</volume><fpage>e106</fpage><lpage>e116</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(13)70145-1</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>KHC</given-names></name><name><surname>Madigan</surname><given-names>MC</given-names></name><name><surname>Billson</surname><given-names>FA</given-names></name><name><surname>Penfold</surname><given-names>PL</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Differential expression of GFAP in early v late AMD: a quantitative analysis</article-title><source>The British Journal of Ophthalmology</source><volume>87</volume><fpage>1159</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1136/bjo.87.9.1159</pub-id><pub-id pub-id-type="pmid">12928288</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xin</surname><given-names>X</given-names></name><name><surname>Rodrigues</surname><given-names>M</given-names></name><name><surname>Umapathi</surname><given-names>M</given-names></name><name><surname>Kashiwabuchi</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>T</given-names></name><name><surname>Babapoor-Farrokhran</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Bhutto</surname><given-names>I</given-names></name><name><surname>Welsbie</surname><given-names>DS</given-names></name><name><surname>Duh</surname><given-names>EJ</given-names></name><name><surname>Handa</surname><given-names>JT</given-names></name><name><surname>Eberhart</surname><given-names>CG</given-names></name><name><surname>Lutty</surname><given-names>G</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name><name><surname>Montaner</surname><given-names>S</given-names></name><name><surname>Sodhi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hypoxic retinal Muller cells promote vascular permeability by HIF-1-dependent up-regulation of angiopoietin-like 4</article-title><source>PNAS</source><volume>110</volume><fpage>E3425</fpage><lpage>E3434</lpage><pub-id pub-id-type="doi">10.1073/pnas.1217091110</pub-id><pub-id pub-id-type="pmid">23959876</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Increased endometrial expression of CC-chemokine receptor-1 in women with adenomyosis</article-title><source>Histology and Histopathology</source><volume>29</volume><fpage>1153</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.14670/HH-29.1153</pub-id><pub-id pub-id-type="pmid">24599574</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>B</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Guan</surname><given-names>H</given-names></name><name><surname>Ji</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Involvement of P2X<sub>7</sub> receptors in retinal ganglion cell apoptosis induced by activated Müller cells</article-title><source>Experimental Eye Research</source><volume>153</volume><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2016.10.005</pub-id><pub-id pub-id-type="pmid">27720859</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Elner</surname><given-names>SG</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Field</surname><given-names>MG</given-names></name><name><surname>Petty</surname><given-names>HR</given-names></name><name><surname>Elner</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>MCP-1-activated monocytes induce apoptosis in human retinal pigment epithelium</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>52</volume><fpage>6026</fpage><lpage>6034</lpage><pub-id pub-id-type="doi">10.1167/iovs.10-7023</pub-id><pub-id pub-id-type="pmid">21447688</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Elevated immunoreactivity of RANTES and CCR1 correlate with the severity of stages and dysmenorrhea in women with deep infiltrating endometriosis</article-title><source>Acta Histochemica</source><volume>115</volume><fpage>434</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.acthis.2012.10.006</pub-id><pub-id pub-id-type="pmid">23219091</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>JRW</given-names></name><name><surname>Sepp</surname><given-names>T</given-names></name><name><surname>Matharu</surname><given-names>BK</given-names></name><name><surname>Khan</surname><given-names>JC</given-names></name><name><surname>Thurlby</surname><given-names>DA</given-names></name><name><surname>Shahid</surname><given-names>H</given-names></name><name><surname>Clayton</surname><given-names>DG</given-names></name><name><surname>Hayward</surname><given-names>C</given-names></name><name><surname>Morgan</surname><given-names>J</given-names></name><name><surname>Wright</surname><given-names>AF</given-names></name><name><surname>Armbrecht</surname><given-names>AM</given-names></name><name><surname>Dhillon</surname><given-names>B</given-names></name><name><surname>Deary</surname><given-names>IJ</given-names></name><name><surname>Redmond</surname><given-names>E</given-names></name><name><surname>Bird</surname><given-names>AC</given-names></name><name><surname>Moore</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Complement C3 variant and the Risk of Age-Related Macular Degeneration</article-title><source>New England Journal of Medicine</source><volume>357</volume><fpage>553</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa072618</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>C-R</given-names></name><name><surname>Mahdi</surname><given-names>RR</given-names></name><name><surname>Oh</surname><given-names>H-M</given-names></name><name><surname>Amadi-Obi</surname><given-names>A</given-names></name><name><surname>Levy-Clarke</surname><given-names>G</given-names></name><name><surname>Burton</surname><given-names>J</given-names></name><name><surname>Eseonu</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Chan</surname><given-names>C-C</given-names></name><name><surname>Egwuagu</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Suppressor of cytokine signaling-1 (SOCS1) inhibits lymphocyte recruitment into the retina and protects SOCS1 transgenic rats and mice from ocular inflammation</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>52</volume><fpage>6978</fpage><lpage>6986</lpage><pub-id pub-id-type="doi">10.1167/iovs.11-7688</pub-id><pub-id pub-id-type="pmid">21778271</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>A</given-names></name><name><surname>Hsiao</surname><given-names>Y-J</given-names></name><name><surname>Chen</surname><given-names>H-Y</given-names></name><name><surname>Chen</surname><given-names>H-W</given-names></name><name><surname>Ho</surname><given-names>C-C</given-names></name><name><surname>Chen</surname><given-names>Y-Y</given-names></name><name><surname>Liu</surname><given-names>Y-C</given-names></name><name><surname>Hong</surname><given-names>T-H</given-names></name><name><surname>Yu</surname><given-names>S-L</given-names></name><name><surname>Chen</surname><given-names>JJW</given-names></name><name><surname>Yang</surname><given-names>P-C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Opposite effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>14273</elocation-id><pub-id pub-id-type="doi">10.1038/srep14273</pub-id><pub-id pub-id-type="pmid">26399191</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zhuang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comprehensive analysis of vitreous chemokines involved in ischemic retinal vein occlusion</article-title><source>Molecular Vision</source><volume>25</volume><fpage>756</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">31814701</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Roychoudhury</surname><given-names>J</given-names></name><name><surname>Doggett</surname><given-names>TA</given-names></name><name><surname>Apte</surname><given-names>RS</given-names></name><name><surname>Ferguson</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Age-dependent changes in FasL (CD95L) modulate macrophage function in a model of age-related macular degeneration</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>54</volume><fpage>5321</fpage><lpage>5331</lpage><pub-id pub-id-type="doi">10.1167/iovs.13-12122</pub-id><pub-id pub-id-type="pmid">23821188</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong-feng</surname><given-names>W</given-names></name><name><surname>Xiong-li</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Glutamate receptor-mediated retinal neuronal injury in experimental glaucoma</article-title><source>Acta Physiol Sin</source><volume>68</volume><fpage>483</fpage><lpage>491</lpage></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81208.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bernstein</surname><given-names>Audrey M</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040kfrw16</institution-id><institution>State University of New York Upstate Medical University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2023.01.03.522541" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2023.01.03.522541"/></front-stub><body><p>Immune cell invasion, gliosis, and photoreceptor cell death are observed in multiple retinal diseases. This important study identifies cells and signaling pathways that connect these three processes during retinal degeneration. The authors provide convincing experimental evidence linking macrophages to the activation of retinal Müller glial cells and photoreceptor death. These results are significant as they identify cell types and potential targets linking immune cells to retinal cell changes, ultimately resulting in photoreceptor cell death.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81208.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Bernstein</surname><given-names>Audrey M</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040kfrw16</institution-id><institution>State University of New York Upstate Medical University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Zuber</surname><given-names>Michael E</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01q1z8k08</institution-id><institution>SUNY Upstate Medical University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Apte</surname><given-names>Rajendra S</given-names></name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2023.01.03.522541">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2023.01.03.522541v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;CCR1 Mediates Müller Cell Activation and Photoreceptor Cell Death in Macular and Retinal Degeneration&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: Michael E Zuber (Reviewer #1); Rajendra S. Apte (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Main controls to include for a revision would be injecting non-AMD monocytes as controls, tracing monocyte development into macrophages, proof that macrophages migrated into the subretinal space, appropriate M1 markers, a demonstration that M2a cells induce apoptosis in vivo, improving ROS-related data, and more on MPIF1 or MCP4.</p><p>Discussion of other main concerns would be that the photic injury model is limited in its reflection of human AMD. Also, the rd10 model of phosphodiesterase is a model of retinitis pigmentosa and not AMD.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>It would be interesting to examine the role of these M2a cells that are identified in surrogate murine models of retinal disease e.g. laser injury-induced CNV or lipid-induced retinal degeneration</p><p>The role of macrophage polarization was examined and published in retinal models starting in 2006. As the authors develop their interesting research based on these initial studies it would be appropriate to reference the papers listed below so that the literature is presented in the appropriate context:</p><p>PMID: 17975672</p><p>PMID: 16903779</p><p>PMID: 31422901</p><p>PMID: 23562078</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>The authors perform an elegant study where they show that intravitreal injection of human monocytes from patients with AMD cause reduced ERG B-wave amplitudes and photoceptor cell loss compared to controls in the photic retinal injury model. Differentiation of human monocytes from patients with AMD into M2a macrophages caused increased photoreceptor cell loss compared to M1 macrophages. This is an interesting finding as I may have expected that pro-inflammatory M1 macrophages caused more photoreceptor loss. Could the authors clarify how many times the experiment was repeated? I see that n=8 mice were used for each group; however, it's important that the experiment be repeated multiple times. Next, the authors show that after co-culturing retinal explants with M1 and M2a human macrophages followed by TUNEL staining, M2 human macrophages had significantly more apoptotic photoreceptor cells than M1 human macrophages. The authors show that human M2a macrophages have significantly more ROS compared to M0 and M1 human macrophages; however, injection of human M2a macrophages did not cause increased oxidative damage compared to control conditions. Using a multiplex cytokine assay of 120 cytokines between human M1 and M2a macrophages-conditioned medium, the authors found increased levels of 9 cytokines, including three HCC-1, MCP-4, and MPIF-1, which are ligands of the C-C chemokine receptor CCR1. Co-staining showed CCR1 expression in Muller cells following photic injury. In the rd10 mouse model of retinal degeneration as well as aged BALB/c mice CCR1 is upregulated in Muller cells. Injection of mice with the CCR1-specific inhibitor BX471 caused increased photoreceptor numbers and B-wave amplitudes in the photic-injury model. Overall the experiments are well performed; however, the photic injury model is limited in its reflection of human AMD. While it's outside of the scope of this paper, it would be nice to see these pathways validated in human-diseased AMD tissue. I agree with the authors that human M2a macrophages mediate neurotoxicity in the photic injury model; however, the limitation of this study is that the authors don't directly provide evidence of this pathway in human tissue and may not accurately represent human AMD. Further, the rd10 model of phosphodiesterase is a model of retinitis pigmentosa and not AMD, so it's possible that the CCR1 inhibitor may be more applicable in retinitis pigmentosa than AMD. It's also unclear whether the role of CCR1 activation is mediated through Muller cells or immune cell infiltration as monocytes express CCR1. Thus additional research would need to be performed to define the cell-type specificity of CCR1-inhibition in this model and to show whether CCR1 antagonists are translational to human AMD. However, this is a well-performed study and of interest to the field.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81208.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Main controls to include for a revision would be injecting non-AMD monocytes as controls, tracing monocyte development into macrophages, proof that macrophages migrated into the subretinal space, appropriate M1 markers, a demonstration that M2a cells induce apoptosis in vivo, improving ROS-related data, and more on MPIF1 or MCP4.</p><p>Discussion of other main concerns would be that the photic injury model is limited in its reflection of human AMD. Also, the rd10 model of phosphodiesterase is a model of retinitis pigmentosa and not AMD.</p><p>Reviewer #2 (Recommendations for the authors):</p><p>It would be interesting to examine the role of these M2a cells that are identified in surrogate murine models of retinal disease e.g. laser injury-induced CNV or lipid-induced retinal degeneration</p></disp-quote><p>Thank you for this important comment. We previously assess the role of M1 and M2a cells from AMD patients in laser injury- induced CNV in rat (Hagbi-Levi S et al., 2016). We showed that adoptive transfer of M1 cells is associated with larger CNV compared with adoptive transfer of M2a macrophages.</p><disp-quote content-type="editor-comment"><p>The role of macrophage polarization was examined and published in retinal models starting in 2006. As the authors develop their interesting research based on these initial studies it would be appropriate to reference the papers listed below so that the literature is presented in the appropriate context:</p><p>PMID: 17975672</p><p>PMID: 16903779</p><p>PMID: 31422901</p><p>PMID: 23562078</p></disp-quote><p>Thank you for this comment. We have added references to these important earlier reports that provided solid information and the basis to continue research in the field.</p><p>PMID: 17975672- Line 99</p><p>PMID: 16903779- Line 78</p><p>PMID: 31422901- Line 86</p><p>PMID: 23562078- Line 99</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>The authors perform an elegant study where they show that intravitreal injection of human monocytes from patients with AMD cause reduced ERG B-wave amplitudes and photoceptor cell loss compared to controls in the photic retinal injury model. Differentiation of human monocytes from patients with AMD into M2a macrophages caused increased photoreceptor cell loss compared to M1 macrophages. This is an interesting finding as I may have expected that pro-inflammatory M1 macrophages caused more photoreceptor loss. Could the authors clarify how many times the experiment was repeated? I see that n=8 mice were used for each group; however, it's important that the experiment be repeated multiple times.</p></disp-quote><p>The in vivo experiments were repeated 8 times; each of the blood samples was from a different AMD patient, and PBMCs were isolated and polarized into M0, M1, M2a and M2c macrophages from each patient. Additionally, we have validated the results in ex-vivo experiments with samples from different patients, testing 6 replicates, and the results were in agreement with the in vivo experiments. It seems that polarized macrophages can have variable effect depending on the microenvironmental context and the origin of the macrophages. For example, we have previously demonstrated that polarized macrophages from AMD patients and unaffected controls can have different effects (Hagbi-Levi et al. 2016).</p><disp-quote content-type="editor-comment"><p>Next, the authors show that after co-culturing retinal explants with M1 and M2a human macrophages followed by TUNEL staining, M2 human macrophages had significantly more apoptotic photoreceptor cells than M1 human macrophages. The authors show that human M2a macrophages have significantly more ROS compared to M0 and M1 human macrophages; however, injection of human M2a macrophages did not cause increased oxidative damage compared to control conditions. Using a multiplex cytokine assay of 120 cytokines between human M1 and M2a macrophages-conditioned medium, the authors found increased levels of 9 cytokines, including three HCC-1, MCP-4, and MPIF-1, which are ligands of the C-C chemokine receptor CCR1. Co-staining showed CCR1 expression in Muller cells following photic injury. In the rd10 mouse model of retinal degeneration as well as aged BALB/c mice CCR1 is upregulated in Muller cells. Injection of mice with the CCR1-specific inhibitor BX471 caused increased photoreceptor numbers and B-wave amplitudes in the photic-injury model. Overall the experiments are well performed; however, the photic injury model is limited in its reflection of human AMD. While it's outside of the scope of this paper, it would be nice to see these pathways validated in human-diseased AMD tissue. I agree with the authors that human M2a macrophages mediate neurotoxicity in the photic injury model; however, the limitation of this study is that the authors don't directly provide evidence of this pathway in human tissue and may not accurately represent human AMD.</p></disp-quote><p>Thank you for this comment. As the reviewer mentioned, the study of human AMD tissue is beyond the scope of the current ms. We have tested macrophages derived from humans and show their function in ex vivo and in vivo models. Thus, results of this study suggest that M2a macrophages may potentially have a role in AMD, but, validation of these findings in humans is required. Nevertheless, recent studies performed in human AMD samples supported the results presented in our manuscript. Joo et al. (2021) showed increased level of two ligands of CCR1, MIP-1α and MIP-1β, in aqueous humour from AMD patients compared with age-matched control. Also, Saddala et al. (2019), revealed increased expression of CCR1, of its ligands (MIP-1α and MIP-1β) and Muller gliosis-related genes (CXCL10, CCL2) in the human peripheral retina and RPE-choroid-sclera of AMD patient. These data support our finding regarding a potential involvement of CCR1 in AMD. The text of the revised ms. was revised accordingly in the Discussion section and the above mentioned references were added to the ms. (Lines 459-464).</p><disp-quote content-type="editor-comment"><p>Further, the rd10 model of phosphodiesterase is a model of retinitis pigmentosa and not AMD, so it's possible that the CCR1 inhibitor may be more applicable in retinitis pigmentosa than AMD. It's also unclear whether the role of CCR1 activation is mediated through Muller cells or immune cell infiltration as monocytes express CCR1. Thus additional research would need to be performed to define the cell-type specificity of CCR1-inhibition in this model and to show whether CCR1 antagonists are translational to human AMD.</p></disp-quote><p>Thank you for this comment. We agree that CCR1 expression on both Muller cells and macrophages can potentially mediate retinal cell death in aAMD. This possibility is discussed in the revised manuscript (Lines 510-519 and 536-542). Our results show that it is possible that CCR1 can potentially mediate retinal cell death in retinitis pigmentosa. We have detailed this issue in the Discussion section of the revised ms. (Lines 459-464).</p><disp-quote content-type="editor-comment"><p>However, this is a well-performed study and of interest to the field.</p></disp-quote><p>Thank you!</p></body></sub-article></article>